Bioluminescent detection of DNA synthesis

Abstract

Provided herein are reagents and methods for incorporating modified nucleotides into DNA and detecting DNA synthesis. In particular, haloalkyl modified nucleobases are provided for incorporation into nucleic acids for detection by bioluminescent binding agents.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 63 / 188,259, filed May 13, 2021, which is incorporated herein by reference.

[0002] Field Provided herein are reagents and methods for incorporating modified nucleotides into DNA and detecting DNA synthesis. In particular, haloalkyl modified nucleobases are provided for incorporation into nucleic acids for detection by bioluminescent binding agents. [Background technology]

[0003] Several methods and kits are available for measuring cell proliferation, including measuring changes in the number of viable cells using various viability assays. However, the most direct and accurate way to measure cell proliferation is by measuring the synthesis of new DNA. Initially, this was done by incorporation of radioactive nucleosides (e.g. H-thymidine). However, to avoid radioactivity, other non-radioactive methods have been developed that use modified nucleoside analogues, e.g., bromo-deoxyuridine (BrdU) and 5-ethynyl-2'-deoxyuridine (Edu). During cell replication, deoxyuridine nucleoside analogues are incorporated into replicating DNA instead of thymidine. BrdU incorporation is detected by anti-BrdU antibodies using standard ELISA. Edu contains an alkyne group and is detected by chemical reaction with an azide containing fluorescent probe. Summary of the Invention

[0004] Provided herein are reagents and methods for incorporating modified nucleotides into DNA and detecting DNA synthesis (and / or cell proliferation). In particular, haloalkyl modified nucleobases are provided for incorporation into nucleic acids for detection by bioluminescent binding agents.

[0005] In some embodiments, provided herein is a compound of formula (I): [ka] or a salt thereof, wherein B is a nucleobase or a modified nucleobase, including, but not limited to, a modified adenine, guanine, uracil, or cytosine; L is a linker; and A is a haloalkyl group. In some embodiments, the compound or salt thereof is [ka] Contains one of the following:

[0006] In some embodiments, L comprises one or more groups independently selected from alkyl, cyclic alkyl, alkylene, alkenylene, alkynylene, arylene, -O-, -NH-, and -C(O)-. In some embodiments, L is -(CH2) m In some embodiments, L is one or more groups selected from: -, -CH=CH-, -C≡C-, -C(O)NH-, -OC(O)NH-, -CHCHO-, and -CHO-, where m is 1 to 6. [ka] [ka] wherein p, q, r, and s are each independently 1 to 6. In some embodiments, L is C≡C-L', where L' is alkyl, cyclic alkyl, alkylene, alkenylene, alkynylene, arylene, -O-, -NH-, -C(O)-, -(CH2) m In some embodiments, A is selected from -, -CH=CH-, -C≡C-, -C(O)NH-, -OC(O)NH-, -CHCHO-, and -CHO-, where m is 1 to 6. 12 In some embodiments, A is -(CH2) n-X, where n is 4, 5, 6, 7, or 8, and X is halo. In some embodiments, X is Cl or Br. In some embodiments, n is 6. In some embodiments, X is Cl.

[0007] In some embodiments, the compound of formula (II) is: [ka] wherein p, q, r and s are independently 1 to 6.

[0008] In some embodiments, the compound of formula (III) is: [ka] wherein p, q, r and s are independently 1 to 6.

[0009] In some embodiments, the compound of formula (IV) is: [ka] is selected from In the formula, p, q, r and s are independently 1 to 6.

[0010] In some embodiments, the compound of formula (V) is: [ka] is selected from In the formula, p, q, r and s are independently 1 to 6.

[0011] In some embodiments, the compound is: [ka] [ka] [ka] [ka] [ka] [ka] is selected from.

[0012] In some embodiments, provided herein is a compound of formula (IV): [ka] or a salt thereof, wherein L is a linker; and A is a haloalkyl group. In some embodiments, L comprises one or more groups independently selected from alkylene, alkenylene, alkynylene, arylene, -O-, -NH-, and -C(O)-. In some embodiments, L comprises one or more groups independently selected from -CH2-, -C≡C-, -C(O)NH-, -OC(O)NH-, -CH2CHO-, and phenylene. In some embodiments, L is selected from the following: [ka] [ka] wherein p, q, r, and s are each independently 1 to 6. In some embodiments, L is selected from: [ka] In some embodiments, A is selected from C2-C 12 In some embodiments, L is C≡C-L′, where L′ is an alkyl, cyclic alkyl, alkylene, alkenylene, alkynylene, arylene, —O—, —NH—, —C(O)—, —(CH2) mIn some embodiments, A is selected from the group consisting of -, -CH=CH-, -C≡C-, -C(O)NH-, -OC(O)NH-, -CHCHO-, and -CHO-, where m is 1 to 6. In some embodiments, A is selected from the group consisting of -, -CH=CH-, -C≡C-, -C(O)NH-, -OC(O)NH-, -CHCHO-, and -CHO-, where m is 1 to 6. -(CH2) n -X; where n is 4, 5, 6, 7, or 8, and X is halo. In some embodiments, n is 6 and X is chloro. In certain embodiments, the compound has the following: [ka] In some embodiments, the compound is selected from: [ka] [ka] is selected from In the formula, p, q, r and s are independently 1 to 6.

[0013] In some embodiments, polynucleotide strands are provided that include deoxyadenosine, deoxythymidine, deoxycytidine, deoxyguanosine, and haloalkyl-modified deoxyuridine as described herein. In other embodiments, polynucleotides are provided that include one or more of deoxyadenosine, deoxythymidine, deoxycytidine, deoxyguanosine, and haloalkyl-modified deoxyuridine, haloalkyl-modified deoxyadenosine, haloalkyl-modified deoxycytidine, and haloalkyl-modified deoxyguanosine.

[0014] In some embodiments, provided herein are methods of labeling a nucleic acid, comprising including a haloalkyl-modified deoxynucleotide described herein with other deoxynucleotides, a template DNA, and a DNA polymerase, and allowing the DNA polymerase to incorporate the haloalkyl-modified deoxynucleotides described herein and the other deoxynucleotides into a newly synthesized, labeled nucleic acid.

[0015] In some embodiments, provided herein is a method of labeling a nucleic acid in a cell with a haloalkyl group, the method comprising contacting a cell with a haloalkyl-modified deoxynucleoside described herein and introducing the haloalkyl-modified deoxynucleoside into the cell. The cellular machinery then converts the haloalkyl-modified deoxynucleoside into a haloalkyl-modified deoxynucleotide triphosphate, which is incorporated into the cell's nucleic acid during DNA synthesis in place of a portion of the corresponding unmodified nucleotide. In some embodiments, the cell is cultured in a medium containing the haloalkyl-modified deoxynucleoside. An embodiment utilizing a haloalkyl-modified deoxyuridine is exemplified herein to generally demonstrate the broader utility of haloalkyl-modified deoxynucleosides.

[0016] In some embodiments, provided herein are nucleic acids (e.g., nucleic acids comprising one or more haloalkyl modified deoxynucleotides) produced by the methods herein. In some embodiments, provided herein are cells comprising nucleic acids produced by the methods herein.

[0017] In some embodiments, provided herein are methods (e.g., detecting nucleic acids in cells, monitoring DNA synthesis, monitoring cell proliferation, etc.) that include: (a) identifying a nucleic acid with a haloalkyl group by the methods herein; (b) lysing the cells to produce a cell lysate containing the haloalkyl-labeled nucleic acid; (c) contacting the cell lysate with (i) a first fusion of (A) a first modified dehalogenase enzyme capable of covalently binding to a haloalkyl group and (B) a peptide component of a luminescent complex; (ii) a second fusion of (A) a second modified dehalogenase enzyme capable of covalently binding to a haloalkyl group and (B) a polypeptide component of a luminescent complex, and (iii) a substrate for the luminescent complex; and (d) detecting luminescence from the luminescent complex, wherein the luminescence indicates a sufficient density of haloalkyl incorporation on the nucleic acid to allow for joining of the first fusion and the second fusion at a location along the nucleic acid that promotes formation of a luminescent complex. In some embodiments, the first modified dehalogenase enzyme and the second modified dehalogenase enzyme have at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 100%, or any ranges therebetween) sequence identity to SEQ ID NO:16. In some embodiments, a peptide component of the luminescent complex has at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 100%, or any ranges therebetween) sequence identity to SEQ ID NO:10. In some embodiments, a polypeptide component of the luminescent complex has at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 100%, or any ranges therebetween) sequence identity to SEQ ID NO:9. In some embodiments, the peptide component of the luminescent complex has at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 100%, or any range therebetween) sequence identity to SEQ ID NO: 14. In some embodiments, the polypeptide component of the fluorescent complex has at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 100%, or any range therebetween) sequence identity to SEQ ID NO: 12.In some embodiments, the substrate for the luminescent conjugate comprises coelenterazine, furimazine, or an analog or derivative of coelenterazine.

[0018] In some embodiments, provided herein are methods (for detecting nucleic acids in a cell, monitoring DNA synthesis, monitoring cell proliferation, etc.) that include: (a) labeling a nucleic acid with a haloalkyl group according to the methods herein; (b) expressing in the cell: (i) a first fusion (e.g., that induces expression of): (A) a first fusion of (A) a first modified dehalogenase enzyme capable of covalently binding to a haloalkyl group and (B) a first fusion with a peptide component of a light-emitting complex; (ii) a second fusion of (A) a second modified dehalogenase enzyme capable of covalently binding to a haloalkyl group and (B) a second fusion with a polypeptide component of a light-emitting complex; (c) contacting the cell with a substrate for the light-emitting complex; and (d) detecting luminescence from the light-emitting complex, wherein the luminescence indicates that the density of haloalkyl labels on the nucleic acid is sufficient to allow binding of the first fusion and the second fusion at a location along the nucleic acid that promotes formation of a light-emitting complex. In some embodiments, the first modified dehalogenase enzyme and the second modified dehalogenase enzyme have at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 100%, or any ranges therebetween) sequence identity to SEQ ID NO:16. In some embodiments, a peptide component of the luminescent complex has at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 100%, or any ranges therebetween) sequence identity to SEQ ID NO:10. In some embodiments, a polypeptide component of the luminescent complex has at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 100%, or any ranges therebetween) sequence identity to SEQ ID NO:9. In some embodiments, the peptide component of the luminescent conjugate has at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 100%, or ranges therebetween) sequence identity to SEQ ID NO: 14. In some embodiments, the polypeptide component of the fluorescent conjugate has at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 100%, or ranges therebetween) sequence identity to SEQ ID NO: 12. In some embodiments, the substrate for the luminescent conjugate comprises coelenterazine, furimazine, or an analog or derivative of coelenterazine.

[0019] In some embodiments, provided herein is a method (such as detecting nucleic acid in a cell, monitoring DNA synthesis, monitoring cell proliferation, etc.) that includes: (a) modifying a nucleic acid with a haloalkyl group by the methods herein; (b) lysing the cells to produce a cell lysate containing a haloalkyl-labeled nucleic acid; (c) contacting the cell lysate with (i) a fusion of (A) a modified dehalogenase enzyme capable of covalently binding a haloalkyl group with (B) a photoprotein; and (iii) a substrate for a light-emitting complex; and (d) detecting luminescence from the photoprotein, wherein the luminescence is proportional to the amount of haloalkyl-labeled nucleic acid. In some embodiments, the polypeptide component of the photoprotein has at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 100%, or a range therebetween) sequence identity with SEQ ID NO:5. In some embodiments, the substrate for the photoprotein includes coelenterazine, furimazine, or an analog or derivative of coelenterazine. In some embodiments, the first modified dehalogenase enzyme and the second modified dehalogenase enzyme have at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 100%, or ranges therebetween) sequence identity to SEQ ID NO:16.

[0020] In some embodiments, provided herein are methods for detecting a nucleic acid in a cell, the methods including: (a) modifying a nucleic acid with a haloalkyl group by the methods herein; (b) lysing the cell to produce a cell lysate comprising the haloalkyl-labeled nucleic acid; (c) contacting the cell lysate with (i) a first fusion of (A) a first modified dehalogenase enzyme capable of covalently binding to a haloalkyl group, and (B) a first peptide component of a luminescent complex; (ii) a second fusion of (A) a second modified dehalogenase enzyme capable of covalently binding to a haloalkyl group, and (B) a second peptide component of a luminescent complex; (iii) a polypeptide component of a luminescent complex; and (iv) a substrate for the luminescent complex; and (d) detecting luminescence from the luminescent complex, wherein the luminescence indicates a sufficient density of haloalkyl labels on the nucleic acid to allow for binding of the first fusion and the second fusion at a location along the nucleic acid that promotes formation of the luminescent complex. In some embodiments, the first modified dehalogenase enzyme and the second modified dehalogenase enzyme have at least 70% sequence identity to SEQ ID NO: 16. In some embodiments, the first peptide component of the luminescent complex has at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 100%, or any ranges therebetween) sequence identity to SEQ ID NO: 13. In some embodiments, the second peptide component of the luminescent complex has at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 100%, or any ranges therebetween) sequence identity to SEQ ID NO: 15. In some embodiments, the polypeptide component of the fluorescent complex has at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 100%, or any ranges therebetween) sequence identity to SEQ ID NO: 12. In some embodiments, the substrate for the luminescent complex comprises coelenterazine or furimazine.

[0021] In some embodiments, provided herein are methods for detecting a haloalkyl-labeled nucleic acid in a cell, the methods comprising: (a) lysing the cell to produce a cell lysate comprising the haloalkyl-labeled nucleic acid; (b) contacting the cell lysate with (i) a modified dehalogenase capable of covalently binding to a haloalkyl group and (ii) a reporter capable of generating a detectable signal; (c) binding the modified dehalogenase to the haloalkyl group on the nucleic acid; and (d) detecting a detectable signal from the reporter. In some embodiments, the reporter is a luciferase (e.g., NANOLUC, firefly luciferase, Renilla luciferase, etc.), a fluorophore (e.g., TAMRA, BODIPY, FAM, etc.), a fluorescent protein (e.g., GFP, CFP, YFP, variants thereof, etc.), or a detectable enzyme (e.g., horseradish peroxidase, alkaline phosphatase, β-galactosidase, acetylcholinesterase, etc.). In some embodiments, the method further comprises between steps (c) and (d) washing away any reporter linked to the modified dehalogenase that is not bound to the haloalkyl-labeled nucleic acid.

[0022] In some embodiments, provided herein are methods of detecting a haloalkyl-labeled nucleic acid in a cell, the methods comprising: (a) lysing the cell to produce a cell lysate comprising the haloalkyl-labeled nucleic acid; (b) contacting the cell lysate with (i) a first fusion of (A) a modified dehalogenase capable of covalently binding to a haloalkyl group and (B) a first component of a reporter complex, and (ii) a second fusion of (A) a modified dehalogenase capable of covalently binding to a haloalkyl group and (B) a second component of a reporter complex, the detectable complex being capable of producing a detectable signal when the first component is in contact with or in physical proximity to the second component; (c) binding the modified dehalogenase to the haloalkyl group on the nucleic acid; and (d) detecting the detectable signal from the reporter complex. In some embodiments, the reporter complex is a split luciferase (e.g., NANOBIT), a split fluorescent protein (e.g., split GFP), or a split detectable enzyme. In some embodiments, "split" refers to a reporter that exists as two or more complementary fragments; when the components of the complex are bound together a greater detectable signal is produced than the individual components.

[0023] In some embodiments, provided herein are methods for detecting a haloalkyl-labeled nucleic acid in a cell by BRET, the method comprising: (a) lysing the cells to produce a cell lysate comprising the haloalkyl-labeled nucleic acid; (b) contacting the cell lysate with (i) (A) a modified dehalogenase capable of covalently attaching a haloalkyl group linked to (B) a reporter capable of emitting light at a first wavelength, and (ii) (A) a modified dehalogenase capable of covalently attaching a haloalkyl group, and (B) a fluorophore having an excitation spectrum that overlaps with the first wavelength and emission spectrum; (c) allowing the modified dehalogenase to bind to the haloalkyl group on the nucleic acid; and (d) detecting a wavelength within the emission spectrum of the fluorophore. In some embodiments, the reporter is a luciferase and emits light at a first wavelength when contacted with a substrate. In some embodiments, the method further comprises contacting the cell lysate with a substrate for the luciferase. In some embodiments, the reporter is a fluorescent protein and emits light at a first wavelength when the fluorescent protein is exposed to a wavelength within the excitation spectrum of the fluorescent protein. In some embodiments, the method further comprises exposing the cell lysate to a wavelength within the excitation spectrum of the fluorescent protein. In some embodiments, the amount of luminescence (or other reporter signal) detected by the methods herein is proportional to the amount of haloalkyl nucleotide incorporated into newly synthesized nucleic acid. In some embodiments, the amount of haloalkyl nucleotide incorporation is proportional to the rate of DNA synthesis in the cell. In some embodiments, the rate of DNA synthesis in the cell is proportional to the rate of cell replication. In some embodiments, the detection comprises monitoring the luminescence (or other reporter signal) over time. In some embodiments, the method further comprises exposing the cell to a stimulus and monitoring the effect of the stimulus on the luminescence (or other reporter signal). In some embodiments, the stimulus results in an alteration (eg, an increase or decrease) in the rate of cell death, the rate of cell replication, and / or the rate of DNA synthesis. [Brief description of the drawings]

[0024] [Figure 1] FIG. 2 is a schematic diagram illustrating steps of an exemplary method described herein. [Figure 2A] Molecular structures of PBI-7931 (top) and PBI-7960 (bottom). [Figure 2B] Luminescence detected after incorporation of haloalkyl-modified nucleosides into newly synthesized DNA and detection using HALOTAG-NANOBIT fusions. [Diagram 3] Inhibition of DNA synthesis by doxorubicin detected by the decrease in enhanced doxorubicin emission following incorporation of haloalkyl-modified nucleosides into newly synthesized DNA and detection using a HALOTAG-NANOBiT fusion. [Figure 4] The modified nucleosides PBI-9391, PBI-9392 and PBI-9393 were incorporated into newly synthesized DNA and detected via NanoBiT. [Diagram 5] Modified nucleosides PBI-9391, PBI-9392, PBI-9393 and PBI-7960 were simultaneously incorporated into newly synthesized DNA and detected via NanoBiT. An increase in light output is seen in the presence of the modified nucleosides. [Figure 6] Incorporation of the modified chloroalkane nucleoside PBI-7960 was detected without DNA denaturation. [Figure 7] Incorporation of the modified chloroalkane nucleoside PBI-9191 was detected directly in cell lysates using NanoBiT without cell fixation or DNA denaturation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. In case of conflict, this document, including definitions, will control. Although preferred methods and materials are described below, methods and materials similar or equivalent to those described herein can also be used in the practice or testing of this disclosure. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and are not intended to be limiting.

[0026] As used herein, the terms "comprise," "include," "having," "has," "can," "contain," and variations thereof are intended to be open-ended transitional phrases, terms, or words that do not exclude the possibility of additional acts or structures. The singular forms "a," "and," and "the" include plural references unless the context clearly dictates otherwise. Many embodiments herein are described using the open "comprising" language. Such embodiments encompass multiple embodiments in the closed form of "consisting of" and / or "consisting essentially of," which may alternatively be claimed or described using such language. The present disclosure also contemplates other embodiments that "comprising," "consisting of," and "consisting essentially of" the embodiments or elements presented herein, whether or not expressly stated.

[0027] For the recitation of numerical ranges herein, each intervening numerical value therebetween to the same degree of precision is expressly contemplated. For example, for the range 6 to 9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0 to 7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are expressly contemplated.

[0028] As used herein, the term "alkyl" refers to an alkyl group having 1 to 16 carbon atoms (C1-C 16 alkyl), e.g., alkyl having 1 to 14 carbon atoms (C1-C 14 Alkyl), 1 to 12 carbon atoms (C1-C 12 Alkyl), 1 to 10 carbon atoms (C1-C 10"alkyl" refers to a straight or branched saturated hydrocarbon chain containing 1 to 8 carbon atoms (C1-C8 alkyl), 1 to 6 carbon atoms (C1-C6 alkyl), or 1 to 4 carbon atoms (C1-C4 alkyl). Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl.

[0029] As used herein, the term "alkylene" refers to an alkylene group having 1 to 16 carbon atoms (C1-C 16 Alkylene, e.g., alkylene having 1 to 10 carbon atoms (C1-C 10 It refers to a divalent group derived from a straight or branched chain hydrocarbon of 1 to 6 carbon atoms (C1-C6 alkylene), or 1 to 6 carbon atoms (C1-C6 alkylene). Representative examples of alkylene include, but are not limited to, -CH2-, -CH2CH2-, -CH(CH3)-, -CH2CH2CH2-, -CH2CH(CH3)-, -CH2CH2CH2CH2-, -CH2CH2CH(CH3)-, -CH2CH2CH2CH2-, -CH2CH2CH(CH3)-, -CH2CH2CH2CH2CH2-, -CH2CH(CH3)CH2CH2-, -CH2CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2-, -CH2CH2CH(CH3)CH2CH2-, -CH2CH2CH2CH2CH2-, -CH2CH2CH(CH3)CH2CH2-, -CH2CH2CH2CH2CH2-, -CH2CH2CH(CH3)CH2CH2-, -CH2CH2CH2CH2CH2-, -CH2CH2CH(CH3)CH2CH2-, -CH2CH2CH2CH2CH2-, and -CH(CH3)CH2CH2CH2CH2-.

[0030] As used herein, the term "alkenyl" refers to a straight or branched hydrocarbon chain containing 2 to 16 carbon atoms and having at least one carbon-carbon double bond. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl.

[0031] As used herein, the term "alkenylene" refers to a divalent group derived from a straight or branched chain hydrocarbon of 2 to 16 carbon atoms and having at least one carbon-carbon double bond. Representative examples of alkenylene include, but are not limited to, -CH=CH-, -CH=CHCH2-, and -CH2CH=CHCH2-.

[0032] As used herein, the term "alkynyl" refers to a straight or branched hydrocarbon chain containing 2 to 16 carbon atoms and having at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited to, ethynyl, propynyl, and butynyl.

[0033] As used herein, the term "alkynylene" refers to a divalent group derived from a straight or branched chain hydrocarbon of 2 to 16 carbon atoms and having at least one carbon-carbon double bond. Representative examples of alkynylene include, but are not limited to, -C≡C-, -C≡CCH2-, and -CH2C≡CCH2-.

[0034] As used herein, the term "aryl" refers to a phenyl group or a bicyclic or tricyclic aromatic fused ring system. An example of a bicyclic fused ring system is a phenyl group attached to a parent molecular moiety and fused to a phenyl group. An example of a tricyclic fused ring system is a phenyl group attached to a parent molecular moiety and fused to two other phenyl groups. Representative examples of bicyclic aryl include, but are not limited to, naphthyl. Representative examples of tricyclic aryl include, but are not limited to, anthracenyl and phenanthrenyl.

[0035] As used herein, the term "arylene" refers to a divalent aryl group, such as a phenylene group (eg, 1,2-phenylene, 1,3-phenylene, and 1,4-phenylene).

[0036] The terms "halogen" and "halo" as used herein mean F, Cl, Br, or I.

[0037] As used herein, the term "haloalkyl" refers to an alkyl group, as defined herein, in which one or more hydrogen atoms are replaced by halogen. For example, 1, 2, 3, 4, 5, 6, 7, or 8 hydrogen atoms may be replaced by halogen, or all hydrogen atoms may be replaced by halogen. Representative examples of haloalkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, perfluoroethyl, 2-fluoro-2-methylpropyl, 3,3,3-trifluoropropyl, 4-chlorobutyl, 5-chloropentyl, 6-chlorohexyl, 7-chloroheptyl, and 8-chlorooctyl.

[0038] Where substituents are specified by their conventional chemical formula written from left to right, these are intended to encompass the substituents resulting from writing the structure from right to left, e.g., -CHCHO- also refers to -OCHCH-, -C(O)NH- also refers to -NHC(O)-, and -OC(O)NH- also refers to -NHC(O)O-.

[0039] As used herein, in chemical structures, the indications: [ka] represents the point of attachment of one moiety to another (eg, a substituent to a core compound).

[0040] "Bioluminescence" refers to the production and emission of light by a chemical reaction catalyzed or enabled by an enzyme, protein, protein complex, or other biological molecule (e.g., a bioluminescent complex). In a typical embodiment, a substrate for a bioluminescent entity (e.g., a bioluminescent protein or bioluminescent complex) is converted by the bioluminescent entity to an unstable form; the substrate subsequently emits light.

[0041] "Complementary" refers to the property of two or more structural elements (e.g., peptides, polypeptides, nucleic acids, small molecules, etc.) that can hybridize, dimerize, or otherwise form a complex with each other. For example, "complementary peptides and polypeptides" can combine to form a complex. Complementary elements may require assistance to form a complex (e.g., from interacting elements), such as, for example, placing the elements in a proper conformation for complementarity, jointly determining the position of complementary elements, lowering the interaction energy for complementarity, etc.

[0042] A "complex" refers to an assembly or aggregate of molecules (e.g., peptides, polypeptides, etc.) that are in direct and / or indirect contact with each other. In one embodiment, "contact" or more specifically "direct contact" means that two or more molecules are sufficiently close that attractive non-covalent interactions, such as van der Waals forces, hydrogen bonding, ionic and hydrophobic interactions, dominate the interaction of the molecules. In such an embodiment, a complex of molecules (e.g., peptides and polypeptides) is formed under assay conditions such that the complex is thermodynamically favored (e.g., compared to the non-aggregated or non-complexed states of its constituent molecules). As used herein, the term "complex" refers to an assembly of two or more molecules (e.g., peptides, polypeptides, or combinations thereof), unless otherwise specified.

[0043] A "fragment" refers to a peptide or polypeptide obtained by dissociation or "fragmentation" of a larger whole entity (e.g., a protein, polypeptide, enzyme, etc.), or a peptide or polypeptide that has been prepared to have the same sequence as is. Thus, a fragment is a subsequence of the whole entity (e.g., protein, polypeptide, enzyme, etc.) from which it is generated and / or engineered. A peptide or polypeptide that is not a subsequence of an existing whole protein is not a fragment (e.g., is not a fragment of an existing protein). A peptide or polypeptide that is "not a fragment of an existing bioluminescent protein" is an amino acid chain that (1) physically exists prior to the design and / or synthesis of the peptide or polypeptide, and (2) is not a subsequence of a protein (e.g., natural or synthetic) that exhibits substantial bioluminescent activity.

[0044] As used herein, "cell impermeable" refers to a compound or moiety that is unable to cross a cell membrane to the extent that an effective amount of the compound or moiety can be delivered intracellularly.

[0045] As used herein, "cell permeable" refers to a compound or moiety that is able to cross a cell membrane to the extent that an effective amount of the compound is delivered inside the cell.

[0046] As used herein, "coelenterazine" refers to naturally occurring ("natural") coelenterazine. As used herein, the term "coelenterazine analogs" or "coelenterazine derivatives" refers to synthetic (e.g., derivatives or variants) and natural analogs thereof, including furimazine, coelenterazine-N, coelenterazine-F, coelenterazine-H, coelenterazine-HCP, coelenterazine-CP, coelenterazine-C, coelenterazine-E, coelenterazine-FCP, bis-deoxycoelenterazine ("coelenterazine-HH"), coelenterazine-I, , coelenterazine-icp, coelenterazine-v, and 2-methylcoelenterazine, in addition to those disclosed in WO2003 / 040100; U.S. Patent Application Publication No. 12 / 056,073 (paragraph

[0086] ), U.S. Patent No. 8,669,103; WO2012 / 061529, U.S. Patent Application Publication No. 2017 / 0233789, and U.S. Patent Application Publication No. 2018 / 0030059, the disclosures of which are incorporated herein by reference in their entirety. In some embodiments, coelenterazine analogs include pro-substrates, such as those described in U.S. Patent Application Publication No. 12 / 056,073; U.S. Patent Application Publication No. 2012 / 0707849; U.S. Patent Application Publication No. 2014 / 0099654, the contents of which are incorporated herein by reference in their entirety.

[0047] As used herein, "peptide" and "polypeptide," unless otherwise specified, refer to a polymeric compound of two or more amino acids joined through a backbone by peptide amide bonds (--C(O)NH--). The term "peptide" generally refers to short amino acid polymers (e.g., chains having fewer than 25 amino acids), whereas the term "polypeptide" generally refers to longer amino acid polymers (e.g., chains having more than 25 amino acids).

[0048] As used herein, "sample," "test sample," "specimen," "sample from a subject," and "patient sample" may be used interchangeably and may be a sample of blood, such as whole blood, tissue, urine, serum, plasma, amniotic fluid, cerebrospinal fluid, placental cells or tissue, endothelial cells, white blood cells, or monocytes. The sample may be obtained from the patient and used directly, or may be pretreated by filtration, distillation, extraction, concentration, centrifugation, inactivation of interfering components, addition of reagents, etc. to modify the properties of the sample in some way, as discussed herein or otherwise known in the art.

[0049] "Sequence identity" refers to the degree to which two polymeric sequences (e.g., peptides, polypeptides, nucleic acids, etc.) have the same sequence composition of monomeric subunits. The term "sequence similarity" refers to the degree to which two polymeric sequences (e.g., peptides, polypeptides, nucleic acids, etc.) have similar polymeric sequences. For example, similar amino acids are those that share the same biophysical characteristics and can be classified into families, such as acidic (e.g., aspartic acid, glutamic acid), basic (e.g., lysine, arginine, histidine), non-polar (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and uncharged polar amino acids (e.g., glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine). "Percent sequence identity" (or "percent sequence similarity") is calculated by: (1) comparing two optimally aligned sequences over a window of comparison (e.g., the length of the longer sequence, the length of the shorter sequence, a specified window); (2) determining the number of positions that contain identical (or similar) monomers (e.g., the same amino acid occurs in both sequences, a similar amino acid occurs in both sequences) to obtain the number of matched positions; (3) dividing the number of matched positions by the total number of positions in the comparison window (e.g., the length of the longer sequence, the length of the shorter sequence, a specified window); and (4) multiplying the result by 100 to obtain the percent sequence identity or percent sequence similarity. For example, if peptide A and peptide B are both 20 amino acids long and have identical amino acids at all but one position, peptide A and peptide B have 95% sequence identity. If the amino acids at the non-identical positions share the same biophysical properties (e.g., both were acidic), peptide A and peptide B will have 100% sequence similarity. As another example, if peptide C is 20 amino acids in length and peptide D is 15 amino acids in length, and 14 of the 15 amino acids of peptide D are identical to a portion of amino acids in peptide C, then peptides C and D have 70% sequence identity, but peptide D has 93.3% sequence identity over the optimal comparison window of peptide C.For purposes of calculating "percent sequence identity" (or "percent sequence similarity") herein, any gap in the aligned sequences is treated as a mismatch at that position.

[0050] As used herein, "subject" and "patient" refer interchangeably to any vertebrate, including, but not limited to, mammals and humans. In some embodiments, the subject may be human or non-human. The subject or patient may be undergoing a form of treatment. As used herein, "mammal" refers to any member of the mammalian class, including, but not limited to, humans, non-human primates, such as chimpanzees, and other ape and monkey species; livestock animals, such as cows, sheep, pigs, goats, llamas, camels, and horses; domestic animals, such as dogs and cats; laboratory animals, including rodents, such as mice, rats, rabbits, guinea pigs, and the like. The term does not denote a particular age or sex. Thus, adult and newborn subjects, regardless of gender, as well as fetuses, are intended to be included within the scope of the term.

[0051] "Subsequence" refers to a peptide or polypeptide that has 100% sequence identity with another, larger peptide or polypeptide, the subsequence being a perfect sequence match for a portion of the larger amino acid chain.

[0052] As used herein, "substantially" means that the recited properties, parameters, and / or values ​​need not necessarily be achieved exactly, but may vary or deviate, including, for example, tolerances, measurement errors, limits of measurement accuracy, and other factors known to those of skill in the art, to an extent that does not interfere with the effect intended to be provided by the property. A substantially absent (e.g., substantially non-luminescent) property or characteristic may be within the noise, below background, below the detection capability of the assay being used, or may be a small fraction (e.g., <1%, <0.1%, <0.01%, <0.001%, <0.00001%, <0.000001%, <0.0000001%) of a significant property (e.g., luminescence intensity of a bioluminescent protein or bioluminescent complex).

[0053] Detailed Description Provided herein are reagents and methods for incorporating modified nucleosides into DNA and detecting DNA synthesis. In particular, haloalkyl modified nucleotides are provided for incorporation into nucleic acids for detection by bioluminescent binding agents.

[0054] In some embodiments, provided herein is the use of haloalkyl-modified nucleoside reagents (e.g., haloalkyl-modified deoxyuridine, haloalkyl-modified deoxycytidine, etc.) in combination with a reporter agent (e.g., a modified dehalogenase that attaches a haloalkyl group (e.g., HALOTAG) and a detectable reporter element (e.g., NANOLUC, NANOBIT, and / or NANOTRIP technology) to detect DNA synthesis. In some embodiments, haloalkyl-modified nucleosides present in the growth medium can enter cells. Within the cell, the cellular machinery converts the haloalkyl-modified deoxynucleoside to a haloalkyl-modified deoxynucleotide triphosphate. The haloalkyl-modified deoxynucleotide triphosphate is then incorporated into newly synthesized DNA within dividing (growing) cells. Culturing cells in medium containing the haloalkyl-modified nucleoside (e.g., deoxyuridine-chloroalkane, deoxyguanosine-bromoalkene, etc.) allows the nucleotide analogs to be taken up by the cells and converted to nucleoside analogs. The haloalkyl-modified deoxyuridine is converted to a haloalkyl-modified uridine-5'-triphosphate analog and incorporated into newly synthesized DNA with significant frequency. For example, haloalkyl-modified deoxyuridine (as described herein) present in the growth medium can enter the cell. The cell converts the haloalkyl-modified deoxyuridine to haloalkyl-modified uridine-5'-triphosphate. In the case of uridine, the haloalkyl-modified uridine-5'-triphosphate is incorporated into the newly synthesized DNA of the growing cell in place of a portion of the deoxythymidine triphosphate. After removing the haloalkyl-modified nucleoside-containing medium (e.g., deoxyuridine-chloroalkane-containing medium), the cells are lysed and the incorporation of the modified nucleoside (e.g., deoxy-uridine-chloroalkane) is detected using a fusion of a haloalkyl-modified substrate (e.g., a chloroalkane (e.g., HALOTAG)) and a modified dehalogenase covalently linked to a detectable reporter (e.g., a fluorophore, a luciferase (e.g., NANOLUC), or a component of a luminescent complex (e.g., NANOBIT, NANOTRIP component).In some embodiments, purified HALOTAG-LgBiT (HT-LgBiT) and HALOTAG-SmBiT (HT-SmBiT) are used as reagents to detect the incorporation of haloalkyl modified nucleotides into newly synthesized DNA. In some embodiments, binding of a reporter fusion (e.g., HT-NANOLUC) to modified nucleotides in a nucleic acid allows for detection of the synthesized nucleic acid (and thus detection of DNA synthesis and / or cell proliferation). In some embodiments, the amount of reporter fusion (e.g., HT-NANOLUC) bound to modified nucleotides in a synthesized nucleic acid allows for quantification of the nucleic acid (and thus quantification of the amount of DNA synthesis and / or cell proliferation). In embodiments in which two or more different reporter fusions are used, each containing a haloalkyl binding moiety (e.g., HALOTAG) and a component of a bioluminescent complex (e.g., a NANOBIT or NANOTRIP component), detection is based on the assumption that if the haloalkyl-modified nucleotide is significantly incorporated into DNA, the two haloalkyl-modified nucleotides will be present frequently enough and in sufficient proximity to observe facile complementation of the components of the bioluminescent complex. For example, when HT-SmBiT and HT-LgBiT bind to adjacent or nearby nucleotides, the two BiTs will come together to generate an active luciferase complex, the activity of which can then be detected. While non-complementary, close binding of two HT-SmBiT or two HT-LgBiT entities can occur, the frequency of complementary binding is sufficient to allow detection. In the presence of a luciferase substrate, luminescence occurs in direct proportion to the amount of haloalkyl-modified nucleotide incorporation into the cell, which is a direct indicator of cell proliferation.

[0055] In some embodiments, provided herein are haloalkyl modified nucleosides (e.g., haloalkyl modified deoxyuridine, haloalkyl modified deoxyadenosine, haloalkyl modified deoxycytidine; haloalkyl modified deoxyguanosine, etc.), which find use, for example, in the DNA synthesis monitoring methods described herein.

[0056] In some embodiments, disclosed herein is a compound of formula (I): [ka] or a salt thereof, wherein: B is a nucleobase or a modified nucleobase, including, but not limited to, a modified adenine, guanine, uracil, or cytosine; L is a linker; and A is a haloalkyl group. In some embodiments, B is selected from: [ka] For example, when B is uracil, certain embodiments herein include haloalkyl modified nucleosides of formula (IV): [ka] or a salt thereof, wherein L is a linker and A is a haloalkyl group. Experiments herein demonstrate the incorporation of haloalkyl-modified deoxyuridine nucleosides into DNA synthesis in cells and the detection / quantification of nucleic acids produced therefrom. Such experiments demonstrate the use of haloalkyl-modified nucleosides in the assays and systems herein. The embodiments herein are not limited to the use of haloalkyl-modified deoxyuridine nucleosides. In some embodiments, B is guanine, adenine and / or cytosine, and the haloalkyl-modified nucleoside is represented by formula (II), (III) and / or (V): [ka] or a salt thereof, wherein L is a linker and A is a haloalkyl group.

[0057] The group L is a linker. A wide variety of linkers may be used in the compounds of formula (I), (II), (III), (IV) and / or (V). In some embodiments, the linker comprises one or more groups independently selected from alkylene, alkenylene, alkynylene, arylene, -O-, -NH-, and -C(O)-. For example, the linker may comprise various combinations of such groups, such as amides (-C(O)NH-), carbamates (-NHC(O)O-), esters (-C(O)O-), ureas (-NHC(O)NH-), and / or oligo- and poly-ethylene glycols (-(CH2CHO) x Linkers having a -) bond or the like may be provided. For example, in some embodiments, L comprises one or more groups selected from -CH2-, -C≡C-, -C(O)NH-, -OC(O)NH-, -CH2CHO-, and phenylene. In some embodiments, any of the aforementioned functional groups may be combined with any linker suitable for use in the compounds and methods herein. Examples of such linkers and compounds incorporating such linkers are provided herein. However, embodiments within the scope of the present specification are not limited to the specific examples provided herein. In some embodiments, a linker may contain two or more atoms (e.g., 2-200 atoms, including 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 atoms, or any range therebetween (e.g., 2-20, 5-10, 15-35, 25-100, etc.)).

[0058] In some embodiments, the linker L has a formula selected from the following: [ka] In some embodiments, L is C≡C-L′, where L′ is alkyl, cyclic alkyl, alkylene, alkenylene, alkynylene, arylene, —O—, —NH—, —C(O)—, —(CH2) m and m is selected from -, -CH=CH-, -C≡C-, -C(O)NH-, -OC(O)NH-, -CHCHO-, and -CHO-, where m is 1 to 6.

[0059] In some embodiments, A is a haloalkyl group. In some embodiments, A comprises a terminal halogen selected from Cl, Br, F, and I. In some embodiments, the terminal halogen is Cl. In some embodiments, the terminal halogen is Br. In some embodiments, A comprises a suitable alkyl chain, such as (CH2)n, where n is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or greater. In some embodiments, A comprises a C2-C 12 -haloalkyl. In some embodiments, A is -(CH) n -X, where n is 4, 5, 6, 7, or 8, and X is halo. In some embodiments, X is Cl or Br. In some embodiments, n is 6. In some embodiments, X is Cl.

[0060] In some embodiments, a compound of formula (Ia) is provided: [ka] wherein L' is a linker. The linker L' can be any group described herein for the linker L (e.g., alkylene, alkenylene, alkynylene, arylene, -O-, -NH-, -C(O)-, amide (-C(O)NH-), carbamate (-NHC(O)O-), ester (-C(O)O-), urea (-NHC(O)NH-), oligo- and poly-ethylene glycol (-(CH2CHO) x-) linkage, -CH2-, -C≡C-, -C(O)NH-, -OC(O)NH-, -CH2CHO-, phenylene, etc. For example, L' may have a formula selected from: [ka] In some embodiments, C≡C-L′ is: [ka] [ka] wherein p, q, r, and s are each independently 1 to 6. In some embodiments, A is a haloalkyl group as described herein. The group A is a haloalkyl group. For example, in some embodiments, A is a C2-C 12 Haloalkyl groups, such as C2-C 10 A is a haloalkyl group or a C2-C8 haloalkyl group. In some embodiments, A is of the formula -(CH2) n In some embodiments, n is 6 and X is Cl, such that A has the formula -(CH2)6-Cl. In some embodiments, the haloalkyl group may be further substituted with substituents that do not interfere with interaction with mutant dehalogenases.

[0061] In such embodiments, A is a substrate for a dehalogenase, e.g., a haloalkane dehalogenase. Systems including mutant hydrolases (e.g., mutant dehalogenases) that are covalently bound to their substrates (e.g., haloalkyl substrates) are described, for example, in U.S. Patent Nos. 7,238,842; 7,425,436; 7,429,472; and 7,867,726, each of which is incorporated herein by reference in its entirety. HALOTAG is a commercially available modified dehalogenase enzyme that forms stable (e.g., covalent) bonds (e.g., ester bonds) with haloalkyl substrates, which find use in embodiments herein.

[0062] In some embodiments, provided herein is a compound of formula (IIa), (IIIa), (IVa), or Va): [ka] wherein A is a haloalkyl group as described herein and L' is a linker containing any of the groups described herein for the linker L (e.g., alkylene, alkenylene, alkynylene, arylene, -O-, -NH-, -C(O)-, amide (-C(O)NH-), carbamate (-NHC(O)O-), ester (-C(O)O-), urea (-NHC(O)NH-), oligo- and poly-ethylene glycols (-(CHCHO) x -) linkage, -CH2-, -C≡C-, -C(O)NH-, -OC(O)NH-, -CH2CHO-, phenylene, etc. For example, L' may have a formula selected from: [ka] In some embodiments, -C≡C-L' is: [ka] [ka] wherein p, q, r and s are each independently 1 to 6.

[0063] In some embodiments, haloalkyl modified nucleosides are provided herein, for example, as described above. In other embodiments, haloalkyl modified nucleobases are provided: [ka] In certain embodiments, haloalkyl modified nucleotide monophosphates are used, such as: [ka] In some embodiments, a haloalkyl modified nucleotide triphosphate is provided: [ka] For haloalkyl-modified nucleobases, haloalkyl-modified nucleotide monophosphates, and haloalkyl-modified nucleotide triphosphates, B, if present, is selected from: [ka] and A and L are selected from any of the A and L groups described herein for haloalkyl modified nucleosides.

[0064] In certain embodiments, compounds of formula (IV) are provided. Such embodiments are fully exemplified herein, demonstrating the use of haloalkyl modified deoxynucleosides in the compositions and methods herein.

[0065] The compounds of formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IIIa), (IIIb), (IIIc), (IIId), (IV), (IVa), (IVb), (IVc), (IVd), (V), (Va), (Vb), (Vc), and (Vd) may be in the form of a salt. The acid salt may be prepared during the final isolation and purification of the compound, or may be prepared separately by reacting a suitable group of the compound, such as an amino group, with a suitable acid. For example, the compound may be dissolved in a suitable solvent, such as, but not limited to, methanol and water, and treated with at least one equivalent of an acid, such as hydrochloric acid. The resulting salt may precipitate, be isolated by filtration, and dried under reduced pressure. Alternatively, the solvent and excess acid may be removed under reduced pressure to provide the salt. Representative salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, isethionate, fumarate, lactate, maleate, methanesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, oxalate, maleate, pivalate, propionate, succinate, tartrate, trichloroacetate, trifluoroacetate, glutamate, para-toluenesulfonate, undecanoate, hydrochloride, hydrobromide, sulfate, phosphate, and the like. The amino groups of the compounds may also be quaternized with alkyl chlorides, bromides, and iodides, such as methyl, ethyl, propyl, isopropyl, butyl, lauryl, myristyl, stearyl, and the like.

[0066] Basic addition salts can be prepared during the final isolation and purification of the disclosed compounds by reaction of the carboxyl group with a suitable base, for example, hydroxides, carbonates or bicarbonates of metal cations such as lithium, sodium, potassium, calcium, magnesium, or aluminum, or organic primary, secondary or tertiary amines. Quaternary amine salts can be prepared, for example, salts derived from methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N'-dibenzylethylenediamine, ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine, and the like.

[0067] The compounds herein may be synthesized by a variety of methods, including those depicted in Scheme 1 and Scheme 2. [ka]

[0068] As depicted in Scheme 1, propargyl alcohol was activated with p-nitrophenyl chloroformate and then reacted with chlorohexyl-PEG2-amine to give propargylhexyl-chloro-PEG2-carbamate, which was coupled to 5-iodo-dU catalyzed by palladium tetrakis and CuI to produce compound PBI 7931.

[0069] PBI 7960 was obtained by using the method described in Scheme 2. Terephthalic acid was coupled to hexylchloro-PEG2-amine under standard HATU coupling conditions to give 4-((2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)carbamoyl)benzoic acid. 4-((2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)carbamoyl)benzoic acid was activated by TSTU and then reacted with propargylamine to produce N1-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)-N4-(prop-2-yn-1-yl)terephthalamide. N1-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)-N4-(prop-2-yn-1-yl)terephthalamide was coupled with 5-iodo-dU catalyzed by palladium tetrakis and CuI to generate compound PBI 7960.

[0070] Compounds (e.g., or of formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IIIa), (IIIb), (IIIc), (IIId), (IV), (IVa), (IVb), (IVc), (IVd), (V), (Va), (Vb), (Vc) and / or (Vd)), and intermediates, may be isolated and purified by methods well known to those skilled in the art of organic synthesis. Examples of conventional methods for isolating and purifying compounds may include, but are not limited to, recrystallization at high or low temperatures, with optional pretreatment with activated charcoal, thin layer chromatography, distillation at various pressures, sublimation under vacuum, and chromatography on solid supports such as silica gel, alumina, or silica derivatized with alkylsilane groups by grinding, as described, for example, in "Vogel's Textbook of Practical Organic Chemistry", 5th edition (1989) by Furniss, Hannaford, Smith, and Tatchell, pub. Longman Scientific & Technical, Essex CM20 2JE, England.

[0071] The reaction conditions and reaction times for each individual step may vary depending on the particular reactants used and the substituents present in the reactants used. The reactions may be worked up in conventional manner, for example by removing the solvent from the residue, and may be further purified according to methods generally known in the art, such as, but not limited to, crystallization, distillation, extraction, trituration and chromatography. Unless otherwise stated, starting materials and reagents are either commercially available or can be prepared by one skilled in the art from commercially available materials using methods described in the chemical literature.

[0072] Routine experimentation, including appropriate manipulation of reaction conditions, reagents and sequences of synthetic routes, protection of any chemical functionality that may not be compatible with the reaction conditions, and deprotection at appropriate points in the reaction sequence of the method, is within the scope of this disclosure. Suitable protecting groups and methods for protecting and deprotecting different substituents using such suitable protecting groups are well known to those skilled in the art, examples of which can be found in the book by Greens entitled Protective Groups in Organic Synthesis (4 th ed.), John Wiley & Sons, NY (2006), which is incorporated herein by reference in its entirety. Synthesis of the compounds of the present disclosure can be accomplished by synthetic schemes described herein and methods analogous to those described in the specific examples.

[0073] Some of the compounds of the present disclosure have at least one asymmetric center. Depending on the nature of various substituents, additional asymmetric centers may exist. Compounds with asymmetric centers may give rise to enantiomers (optical isomers), diastereomers (stereoisomeric configurations), or both, and it is intended that all possible enantiomers and diastereomers in mixtures and pure or partially purified compounds are included within the scope of the present disclosure.

[0074] Independent syntheses of enantiomerically or diastereomerically enriched compounds or their chromatographic separations can be achieved as known in the art by appropriate modification of the methods disclosed herein. The absolute stereochemistry of compounds can be determined using X-ray crystallography by determining the crystal structure of crystalline products or crystalline intermediates that are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration.

[0075] If necessary, racemic mixtures of compounds can be separated, thereby isolating the individual enantiomers. This separation can be carried out by methods well known in the art, such as coupling a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, and then separating the individual diastereomers by standard methods, such as fractional crystallization or chromatography. The coupling reaction is often the formation of a salt using an enantiomerically pure acid or base. The diastereomeric derivative can then be converted to a pure enantiomer by cleavage of the added chiral residue. Racemic mixtures of compounds can also be separated directly by chromatographic methods using chiral stationary phases, a method well known in the art. Alternatively, any enantiomer of a compound can be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.

[0076] The present disclosure also includes isotopically labeled compounds (e.g., isotopically labeled compounds of formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IIIa), (IIIb), (IIIc), (IIId), (IV), (IVa), (IVb), (IVc), (IVd), (V), (Va), (Vb), (Vc), (Vd), etc.) which are represented by the formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IIIa), (IIIb), (IIIc), (IIId), (IV), (IVa), (IVb), (IVc), (IVd), (IV), (IVa), (IVb), (IVc), (IVd), (V), (Va), (Vb), (Vc), (Vd), etc. (II), (IIa), (IIb), (IIc), (IId), (III), (IIIa), (IIIb), (IIIc), (IIId), (IV), (IVa), (IVb), (IVc), (IVd), (V), (Va), (Vb), (Vc), and (Vd), etc., except for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number normally found in nature. Examples of isotopes suitable for incorporation into the disclosed compounds include, but are not limited to, 2 H, 3 H, 13 C. 14 C. 15 N, 18 O. 31 P, 35 S, 18 F, and 36 Isotopically labeled compounds of formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), (III), (IIIa), (IIIb), (IIIc), (IIId), (IV), (IVa), (IVb), (IVc), (IVd), (V), (Va), (Vb), (Vc), (Vd), etc., can generally be prepared by conventional techniques known to those skilled in the art or by processes similar to those described herein by substituting the appropriate isotopically labeled reagents for non-isotopically labeled reagents.

[0077] The present disclosure provides assays, systems and methods for detecting and / or measuring DNA synthesis by monitoring the incorporation of haloalkyl modified nucleosides into newly synthesized DNA. According to these embodiments, the present disclosure provides materials and methods for detecting and / or quantifying DNA that has incorporated haloalkyl modified nucleosides. In some embodiments, bioluminescent / fluorescent polypeptides and / or bioluminescent / fluorescent conjugates are attached to haloalkyl labels on DNA using protein agents (e.g., modified halo-alkane dehydrogenase proteins (e.g., HALOTAG) and the like) that covalently bind to haloalkanes on DNA.

[0078] In some embodiments, provided herein are materials and methods relating to bioassays for detection of haloalkyl-containing DNA using cells or cell lysates. In some embodiments, provided herein are methods for detecting haloalkyl-labeled DNA (e.g., containing haloalkyl-modified nucleosides) and luciferase from Oplophorus gracilirostris, NANOLUC luciferase (Promega Corporation; U.S. Pat. No. 8,557,970; U.S. Pat. No. 8,669,103; incorporated herein by reference in their entireties), NANOBiT (US9,797,889; incorporated herein by reference in their entireties), NanoTrip (U.S. Patent Application Publication No. 2020 / 0270586; incorporated herein by reference in their entireties), and / or other multi-part bioluminescence technologies (International Application No. PCT / US19 / 36844; International Application No. PCT / US20 / 62499 and U.S. Application No. 17 / 105,925; incorporated herein by reference in their entireties). and bioluminescent polypeptides and / or bioluminescent complexes (of peptide(s) and / or polypeptide components that upon complex formation have enhanced luminescence) based on (e.g., structurally, functionally, etc.) a NANOLUC-based luciferase (e.g., NANOLUC-luciferase), and / or a bioluminescent complex (of peptide(s) and / or polypeptide components that upon complex formation have enhanced luminescence). As described herein, the bioassays can incorporate commercially available NANOLUC-based technologies (e.g., NANOLUC-luciferase, NanoBRET, NANOBiT, NanoTrip, NANOGLO, etc.), although in other embodiments various combinations, variations, or derivatives of commercially available NANOLUC-based technologies are utilized.

[0079] PCT Application No. PCT / US2010 / 033449, U.S. Patent No. 8,557,970, PCT Application No. PCT / 2011 / 059018, and U.S. Patent No. 8,669,103 (each of which is incorporated herein by reference in its entirety for all purposes) describe compositions and methods that include bioluminescent polypeptides. Such polypeptides find use in embodiments herein and may be used in conjunction with the compositions, assays, and methods described herein. In some embodiments, the compositions, assays, and methods provided herein include a bioluminescent polypeptide having sequence identity of SEQ ID NO:5 or at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, or a range therebetween) to SEQ ID NO:5. In some embodiments, any of the aforementioned bioluminescent polypeptides are linked (e.g., fused, chemically linked, etc.) to a modified dehalogenase (e.g., HALOTAG) or utilize another system comprised of a complementary binding partner.

[0080] Native Oplophorus gracilirostris luciferase (OgLuc) and the commercially available NANOLUC luciferase (Promega Corporation) each contain ten β (beta) chains (β1, β2, β3, β4, β5, β6, β7, β8, β9, β10) polypeptides. U.S. Patent No. 9,797,889 (incorporated herein by reference in its entirety) describes the development and use of a complementation system that includes a β1-9-like polypeptide and a β10-like peptide (the actual polypeptide and peptide sequences in U.S. Patent No. 9,797,889 differ from the corresponding sequences in NANOLUC and wild-type native OgLuc).

[0081] By combining peptides and polypeptides that collectively correspond to the full set of the 10β (beta) chains of these luciferases, multipartite complementation systems (e.g., bipartite, tripartite, etc.) have been developed. When a set of complementary peptides and polypeptides is combined, a bioluminescent complex is formed under appropriate conditions (e.g., facilitated by binding of a capture agent fused to a complementary component of the capture element). In some embodiments, the peptide and polypeptide components of the bioluminescent complex find use as detection reagents (e.g., fused to a capture agent) for detection of proteins labeled by the compositions and methods described herein (whereby cell death is detected). These multi-part complementation systems are described, for example, in PCT Application No. PCT / US14 / 26354; U.S. Patent No. 9,797,889; U.S. Patent Application Publication No. 2020 / 0270586; International Application No. PCT / US19 / 36844; International Application No. PCT / US20 / 62499 and U.S. Application No. 17 / 105,925, each of which is incorporated by reference in its entirety for all purposes; examples of these technologies are described below.

[0082] PCT Application No. PCT / US14 / 26354 and U.S. Patent No. 9,797,889 (each of which is incorporated herein by reference in its entirety and for all purposes) describe compositions and methods for the assembly of bioluminescent complexes; such complexes, and their peptide and polypeptide components, find use in embodiments herein and may be used in combination with the compositions, assays and methods described herein. In some embodiments, NANOBiT and other related technologies utilize peptide and polypeptide components that upon assembly into complexes, are significantly enhanced (e.g., 2-fold, 5-fold, 10 ... 2 Double, 10 3 Double, 10 4 The fluorescent material exhibits luminescence that is 2x or more times brighter than the fluorescent material.

[0083] In some embodiments, provided herein are polypeptide components having at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, or ranges therebetween) sequence identity to SEQ ID NO: 9. In some embodiments, the polypeptide has less than 100% (e.g., <99%, <98%, <97%, <96%, <95%, <94%, <93%, <92%, <91%, <90%) sequence identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 5, and / or SEQ ID NO: 6. In some embodiments, provided herein are peptide moieties having at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, or ranges therebetween) sequence identity to SEQ ID NO: 10. In some embodiments, the peptides have less than 100% (e.g., <99%, <98%, <97%, <96%, <95%, <94%, <93%, <92%, <91%, <90%) sequence identity to SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 5, and / or SEQ ID NO: 8. In some embodiments, provided herein are peptide components having at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, or ranges therebetween) sequence identity to SEQ ID NO: 11. In some embodiments, the peptides have less than 100% (e.g., <99%, <98%, <97%, <96%, <95%, <94%, <93%, <92%, <91%, <90%) sequence identity to SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 5, and / or SEQ ID NO: 8. In some embodiments, any of the aforementioned peptide or polypeptide components of the bioluminescent complex are conjugated (e.g., fused, chemically conjugated, etc.) to a modified dehalogenase (e.g., HALOTAG) or utilize another system comprised of a complementary binding partner.In some embodiments, provided herein are peptide components having at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, or ranges therebetween) sequence identity to SEQ ID NO: 10. In some embodiments, the peptides have less than 100% (e.g., <99%, <98%, <97%, <96%, <95%, <94%, <93%, <92%, <91%, <90%) sequence identity to SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 5, and / or SEQ ID NO: 8. In some embodiments, any of the aforementioned peptide or polypeptide components of the bioluminescent complex are conjugated (e.g., fused, chemically conjugated, etc.) to a modified dehalogenase (e.g., HALOTAG) or utilize another system comprised of a complementary binding partner.

[0084] U.S. Patent Application Publication No. 2020 / 0270586; International Application No. PCT / US20 / 62499; and U.S. Patent Application Publication No. 17 / 105,925, which are incorporated by reference in their entireties for all purposes, describe compositions, systems, and methods for the assembly of bioluminescent complexes from three or more peptide and polypeptide components. Such complexes, and their peptide and polypeptide components, may be used in combination with the compositions, assays, and methods described herein.

[0085] In some embodiments, provided herein are polypeptide components having at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, or ranges therebetween) sequence identity to SEQ ID NO: 12 or SEQ ID NO: 19. In some embodiments, the polypeptide has less than 100% (e.g., <99%, <98%, <97%, <96%, <95%, <94%, <93%, <92%, <91%, <90%) sequence identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 6, and / or SEQ ID NO: 9.

[0086] In some embodiments, provided herein are peptide components having at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, or ranges therebetween) sequence identity to SEQ ID NO: 11. In some embodiments, the peptides have less than 100% (e.g., <99%, <98%, <97%, <96%, <95%, <94%, <93%, <92%, <91%, <90%) sequence identity to SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 5, and / or SEQ ID NO: 8.

[0087] In some embodiments, provided herein are peptide components having at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, or ranges therebetween) sequence identity to SEQ ID NO: 13. In some embodiments, the peptides have less than 100% (e.g., <99%, <98%, <97%, <96%, <95%, <94%, <93%, <92%, <91%, <90%) sequence identity to SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, and / or SEQ ID NO: 7.

[0088] In some embodiments, provided herein are peptide components having at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, or ranges therebetween) sequence identity to SEQ ID NO: 14. In some embodiments, the peptides have less than 100% (e.g., <99%, <98%, <97%, <96%, <95%, <94%, <93%, <92%, <91%, <90%) sequence identity to SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7, and / or SEQ ID NO: 8. In some embodiments, any of the foregoing peptide or polypeptide components are conjugated (e.g., fused, chemically conjugated, etc.) to a modified dehalogenase (e.g., HALOTAG) or utilize another system comprised of a complementary binding partner.

[0089] PCT Application No. PCT / US13 / 74765; U.S. Patent Application No. 15 / 263,416 (incorporated by reference in its entirety for all purposes) and other patents and applications describe bioluminescence resonance energy transfer (BRET) compositions, assays, and methods (e.g., incorporating NanoLuc®-based technology); such compositions, assays, and methods, as well as bioluminescent polypeptides and their fluorophore-binding components, may be used in combination with the compositions, assays, and methods described herein. In some embodiments, any NANOLUC-based, NANOBiT-based, and / or multipartite NANOLUC-based or related peptides, polypeptides, complexes, fusions, and conjugates may find use in BRET-based applications using the compositions, assays, and methods described herein. For example, haloalkyl incorporation into a nucleic acid via BRET is detected using a first detection agent that includes a haloalkyl binding moiety (e.g., HALOTAG) and a reporter (e.g., luciferase, fluorescent protein, etc.) that emits a signal at a first emission wavelength, and a second detection agent that includes a haloalkyl binding moiety (e.g., HALOTAG) and a fluorescent reporter (e.g., fluorescent protein, fluorophore, etc.) that has an excitation spectrum that overlaps with the first emission wavelength and emits a signal at a second emission wavelength. Other combinations of luminescent and fluorescent moieties (e.g., fused to HALOTAG) may find use in BRET-mediated detection / quantification of haloalkyl modified nucleic acids using the systems and methods described herein.

[0090] As used herein, the term "energy acceptor" refers to any small molecule (e.g., a chromophore), macromolecule (e.g., an autofluorescent protein, a phycobiliprotein, a nanoparticle, a surface, etc.), or molecular complex that generates a readily detectable signal upon energy absorption (e.g., resonance energy transfer). In certain embodiments, the energy acceptor is a fluorophore or other detectable chromophore.Suitable fluorophores include, but are not limited to, xanthene derivatives (e.g., fluorescein, rhodamine, Oregon Green, eosin, Texas Red, etc.), cyanine derivatives (e.g., cyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine, merocyanine, etc.), naphthalene derivatives (e.g., dansyl and prodan derivatives), oxadiazole derivatives (e.g., pyridyloxazole, nitrobenzoxadiazole, benzoxadiazole, etc.), pyrene derivatives (e.g., cascade blue), oxazine derivatives (e.g., Nile red, Nile blue, cresyl violet, oxazine 170, etc.), acridine derivatives (e.g., proflavine, acridine orange, acridine yellow, etc.), arylmethine derivatives (e.g., auramine, crystal violet, malachite green, etc.), tetrapyrrole derivatives (e.g., porphine, phthalocyanine, bilirubin, etc.), CF dyes (Biotium), BODIPY (Invitrogen), ALEXA Examples of such dyes include FLuoR (Invitrogen), DYLIGHT FLUOR (Thermo Scientific, Pierce), ATTO and TRACY (Sigma Aldrich), FluoProbes (Interchim), DY and MEGASTOKES (Dyomics), SULFO CY dyes (CYANDYE, LLC), SETAU AND SQUARE DYES (SETA BioMedicals), QUASAR and CAL FLUOR dyes (Biosearch Technologies), SURELIGHT DYES (APC, RPE, PerCP, Phycobilisomes) (Columbia Biosciences), APC, APCXL, RPE, BPE (Phyco-Biotech), autofluorescent proteins (e.g., YFP, RFP, mCherry, mKate), and quantum dot nanocrystals. In some embodiments, the fluorophore is a rhodamine analog (e.g., a carboxyrhodamine analog), such as a fluorophore described in U.S. Application No. 13 / 682,589, which is incorporated by reference herein in its entirety.In some embodiments, a fluorophore is an acceptor for BRET applications of the technology herein.

[0091] The assays and methods of the present disclosure include the use of luminogenic substrates. "Bioluminescence," as described herein, generally refers to the production and emission of light by a chemical reaction catalyzed or enabled by an enzyme, protein, protein complex, or other biomolecule (e.g., a bioluminescent complex). In a typical embodiment, a luminogenic substrate for a bioluminescent entity (e.g., a bioluminescent protein or bioluminescent complex) is converted by the bioluminescent entity into an unstable form; the substrate then emits light. In the presence of a detection reagent (e.g., a polypeptide component(s) of a bioluminescent complex) and a substrate (e.g., coelenterazine or a coelenterazine analog), a bioluminescent signal is generated. Provided herein are compositions that include a luminogenic substrate, such as coelenterazine or an analog or derivative thereof. Exemplary coelenterazine analogs include coelenterazine-h, coelenterazine-hh, and furimazine.

[0092] In some embodiments, the substrate is coelenterazine, which has the following structure: [ka]

[0093] In some embodiments, the substrate is an analog or derivative of coelenterazine. Exemplary coelenterazine analogs include coelenterazine-h (2-deoxycoelenterazine or 2,8-dibenzyl-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3(7H)-one), coelenterazine-hh (dideoxycoelenterazine or 2,8-dibenzyl-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one), and furimazine (8-benzyl-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one), which have the following structure: [ka]

[0094] Additional exemplary coelenterazine analogs include coelenterazine-n, coelenterazine-f, coelenterazine-hcp, coelenterazine-cp, coelenterazine-c, coelenterazine-e, coelenterazine-fcp, coelenterazine-i, coelenterazine-icp, coelenterazine-v, 2-methylcoelenterazine, etc. In some embodiments, the compound may be a coelenterazine analog described in WO2003 / 040100; U.S. Application No. 12 / 056,073 (paragraph

[0086] ), U.S. Patent No. 8,669,103; WO2012 / 061529, U.S. Patent Application Publication No. 2017 / 0233789, and U.S. Patent Application Publication No. 2018 / 0030059, the disclosures of which are incorporated herein by reference in their entireties. In some embodiments, the coelenterazine analog or derivative includes a pro-substrate, such as those described in U.S. Patent Application Publication No. 12 / 056,073; U.S. Patent Application Publication No. 2012 / 0707849; U.S. Patent Application Publication No. 2014 / 0099654, the entire contents of which are incorporated herein by reference. In some embodiments, the compound is furimazine.

[0095] Coelenterazine and its analogs and derivatives may suffer from challenges associated with reconstitution into buffer systems used in many assays, such as the bioluminescence methods described herein. For example, coelenterazine, or coelenterazine analogs or derivatives, such as furimazine, may dissolve slowly and / or inconsistently in buffers (e.g., due to the heterogeneous microcrystalline nature of the solid material). Dissolution in organic solvents prior to dilution with buffers may provide faster and more consistent results, but coelenterazine compounds may suffer from instability of organic solutions on storage, including both thermal and photoinstability. In some embodiments, the composition further comprises a polymer. As further described herein, the presence of a polymer may stabilize the compound against degradation, and the presence of a polymer may improve the solubility of the compound in water or aqueous solutions.

[0096] The polymer may be a naturally occurring biopolymer or a synthetic polymer. In some embodiments, the polymer is a naturally occurring biopolymer. Suitable naturally occurring biopolymers are carbohydrates, including disaccharides (e.g., trehalose and maltose), and polysaccharides (e.g., pullulan, dextran, and cellulose). Mixtures of naturally occurring biopolymers may also be used. In some embodiments, the polymer is pullulan, a polysaccharide that includes maltotriose repeating units. Maltotriose is a trisaccharide that includes three glucose units linked via α-1,4 glycosidic bonds. The maltotriose units in the pullulan polymer are linked to each other via α-1,6 glycosidic bonds.

[0097] In some embodiments, the polymer is a synthetic polymer. The synthetic polymer may be a homopolymer, copolymer, or block copolymer (e.g., diblock copolymer, triblock copolymer, etc.). Non-limiting examples of suitable polymers include, but are not limited to, polyamines, polyethers, polyamides, polyesters, polycarbamates, polyureas, polycarbonates, polystyrenes, polyimides, polysulfones, polyurethanes, polyacetylenes, polyethylenes, polyethyleneimines, polyisocyanates, polyacrylates, polymethacrylates, polyacrylonitriles, and polyacrylates. Non-limiting examples of specific polymers include poly(caprolactone) (PCL), ethylene vinyl acetate polymer (EVA), poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid) (PLGA), poly(L-lactic acid-co-glycolic acid) (PLLGA), poly(D,L-lactide) (PDLA), poly(L-lactide) (PLLA), poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone-co-glycolide), poly(D,L-lactide-co-PEO-co-D,L-lactide), poly(D,L-lactide-co-PPO ...L-lactide), polyalkyl cyanoacrylates, polyurethanes, poly-L-lysine (PLL), hydroxypropyl methacrylate (HPMA), poly(ethylene glycol), poly-L-glutamic acid, poly(hydroxy acids), polyanhydrides, polyorthoesters, poly(ester amides), polyamides, poly(ester ethers), polycarbonates, polyalkylenes (e.g., polyethylene and polypropylene), polyalkylene glycols (e.g., poly(ethylene glycol) (PEG)), polyalkylene terephthalates (e.g., poly(ethylene terephthalate) and the like), polyvinyl alcohol (PVA), polyvinyl ethers, polyvinyl esters (e.g., poly(vinyl acetate) and the like), polyvinyl halides (e.g., poly(vinyl chloride) (PVC) and the like), polyvinylpyrrolidone, polysiloxanes, polystyrene (PS), polyurethanes, derivatized celluloses (e.g., alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esthers, cellulose esters, cellulose ether ... cellulose, nitrocellulose, hydroxypropyl cellulose, carboxymethyl cellulose, etc.), polymers of acrylic acid (“polyacrylic acid”) (e.g., poly(methyl (meth)acrylate) (PMMA), poly(ethyl (meth)acrylate), poly(butyl (meth)acrylate), poly(isobutyl (meth)acrylate), poly(hexyl (meth)acrylate), poly(isodecyl (meth)acrylate), poly(lauryl (meth)acrylate), poly(phenyl (meth)acrylate), Poly(acrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate), polydioxanone and its copolymers (e.g., polyhydroxyalkanoates, polypropylene fumarate), polyoxymethylene, poloxamers, poly(ortho)esters, poly(butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), trimethylene carbonate, and mixtures and copolymers thereof.

[0098] In addition to the compound and the polymer, the composition may include additional components such as a buffer, a surfactant, a salt, a protein, or any combination thereof. For example, the composition may include a buffer, such as a phosphate buffer, a borate buffer, an acetate buffer, or a citrate buffer, or other common buffers, such as bicine, tricine, tris(hydroxymethyl)aminomethane (tris), N-[tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid (TAPS), 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid (TAPSO), 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), N-[tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid (TES), piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES), 2-(N-morpholino)ethanesulfonic acid (MES), and the like.

[0099] In some embodiments, the composition may include a surfactant. Exemplary surfactants include nonionic surfactants, anionic surfactants, cationic surfactants, and zwitterionic surfactants. For example, the surfactant may be a nonionic surfactant, such as sorbitan 20. In some embodiments, the composition may include a salt, such as sodium chloride, potassium chloride, magnesium chloride, etc. In some embodiments, the composition may include a protein. For example, the composition may include a carrier protein to prevent surface adsorption of a luminogenic enzyme that may be added in a downstream assay. In some embodiments, the protein may be bovine serum albumin (BSA).

[0100] Embodiments herein include the incorporation of haloalkyl modified nucleosides into DNA (and / or DNA exhibiting haloalkyl groups). In some embodiments herein, the haloalkyl groups on the DNA are utilized as a substrate for a dehalogenase, e.g., a haloalkane dehalogenase. Systems including mutant hydrolases (e.g., mutant dehalogenases) that covalently bind to their substrates (e.g., haloalkyl substrates) are described, for example, in U.S. Pat. Nos. 7,238,842; 7,425,436; 7,429,472; and 7,867,726, each of which is incorporated herein by reference in its entirety. HALOTAG is a commercially available modified dehalogenase enzyme that forms stable (e.g., covalent) bonds (e.g., ester bonds) with haloalkyl substrates, which are utilized in embodiments herein. In some embodiments, the modified dehalogenase (eg, HALOTAG) binds (covalently) to a haloalkyl group that was incorporated into DNA during DNA synthesis.

[0101] It has been demonstrated that modified dehalogenases that form covalent bonds with haloalkyl substrates (e.g., HALOTAG) can be incorporated into fusions with other proteins (e.g., reporter proteins (e.g., luciferase) while maintaining the ability to covalently bind their substrates. In some embodiments, provided herein is a fusion of a modified dehalogenase (e.g., HALOTAG) with a detectable reporter (e.g., a bioluminescent protein, a component of a bioluminescent complex, etc.). In some embodiments, upon binding of the modified dehalogenase (e.g., HALOTAG) to the haloalkyl group on the haloalkyl-modified DNA, the DNA is quantified and / or synthesis on the DNA is monitored / quantified.

[0102] Systems and methods are provided herein for modifying DNA with haloalkyl groups during DNA synthesis. In some embodiments, a haloalkyl-modified deoxynucleoside (e.g., deoxyuridine) is provided with other typical components of DNA replication (e.g., a DNA template, a DNA polymerase, unlabeled deoxynucleosides (dA, dT, dC, dG), etc.). In some embodiments, the haloalkyl-modified deoxynucleoside is incorporated into newly synthesized DNA in place of a portion of the doxthymidine (e.g., at a constant or relatively constant rate (e.g., proportional to the ratio of haloalkyl-modified deoxyuridine to deoxythymidine present). This newly synthesized DNA is then detected by exposing it to a binding / detection agent that (i) is capable of binding to the haloalkyl group and (ii) exhibits a detectable property.

[0103] In some embodiments, the binding / detection agent comprises a haloalkyl binding moiety and a detectable moiety. In some embodiments, the haloalkyl binding moiety is a modified dehalogenase that is covalently bound to its haloalkyl group substrate (e.g., HALOTAG). In some embodiments, the detectable moiety is a light-emitting polypeptide, a luciferase enzyme, and / or a component of a light-emitting complex. If the detectable moiety is a light-emitting polypeptide or a luciferase enzyme, the amount of luminescence detected in the presence of newly synthesized DNA (after washing away excess free binding / detection agent) is proportional to the amount of newly synthesized DNA (and the rate of deoxyuridine incorporation into DNA). If the detectable moiety is a component of a light-emitting complex, luminescence is detectable when the haloalkyl-modified deoxyuridine is incorporated into newly synthesized DNA at a density sufficient to allow the complementary component of the light-emitting complex to be bound in close proximity to the newly synthesized DNA.

[0104] In some embodiments, provided herein are methods of modifying a nucleic acid, comprising including a haloalkyl-modified deoxyuridine as described herein with other deoxynucleotides, a template DNA, and a DNA polymerase, and allowing the DNA polymerase to incorporate the haloalkyl-modified deoxyuridine and other deoxynucleotides as described herein into a newly synthesized, labeled nucleic acid. In some embodiments, DNA synthesis is performed intracellularly. In other embodiments, DNA synthesis is performed in a cell lysate or in an in vitro system (e.g., the haloalkyl-modified deoxyuridine is included in an in vitro DNA synthesis system along with other known components required for DNA synthesis).

[0105] In some embodiments, the haloalkyl-modified deoxyuridine is cell-permeable, such that inclusion of the haloalkyl-modified deoxyuridine in a growth medium results in uptake of the haloalkyl-modified deoxyuridine into cells. In such embodiments, cells grown in / on a growth medium containing the haloalkyl-modified deoxyuridine will incorporate the haloalkyl-modified deoxyuridine into newly synthesized DNA. In some embodiments, provided herein is a method of modifying nucleic acid in a cell with a haloalkyl group, the method comprising contacting a cell with a haloalkyl-modified deoxyuridine as described herein, allowing the haloalkyl-modified deoxyuridine to enter the cell and be incorporated into the nucleic acid of the cell during DNA synthesis in place of some of the deoxythymidine nucleotides. In some embodiments, the cells are cultured in a medium containing the haloalkyl-modified deoxyuridine.

[0106] In some embodiments, provided herein is a method of detecting nucleic acid in a cell. The cell is contacted with a haloalkyl-modified deoxyuridine at a concentration sufficient to allow the haloalkyl-modified deoxyuridine to enter the cell and be incorporated into DNA synthesis in place of a portion of the deoxythymidine. In some embodiments, the haloalkyl-modified deoxyuridine is included in a cell growth medium. The cell is then lysed to generate a cell lysate at a selected time point. If the haloalkyl-modified deoxyuridine is incorporated into the cell's nucleic acid by DNA synthesis, the cell lysate will contain a haloalkyl-labeled nucleic acid. The cell lysate is then contacted with a binding / detection agent. The binding / detection agent comprises a haloalkyl binding moiety (e.g., HALOTAG) and a detectable moiety. As described herein, a variety of different detectable moieties find use within the embodiments herein. Suitable detectable moieties include fluorophores, fluorescent proteins, luciferases, and components of a luminescence complex. In a preferred embodiment, the detectable moiety is a component of a bioluminescence complex. When a binding / detection agent comprising a complementary component of a bioluminescent complex binds to the haloalkyl-labeled DNA at a nearby site, light emission occurs in the presence of a substrate for the luminescent complex, thereby allowing the complementation and formation of a luminescent complex. In some embodiments, a component of the bioluminescent complex is selected that does not form a complex in the absence of promotion by a binding partner. In some embodiments, the use of a component of the bioluminescent complex as a detectable moiety facilitates detection without a wash step (because the binding / detection agent does not form a complex in the absence of promotion, the unbound binding / detection agent does not produce significant light emission).

[0107] In certain embodiments, contacting the cell lysate with the binding / detection agent comprises contacting the cell lysate with (i) a first fusion of (A) a first modified dehalogenase enzyme capable of covalently binding to a haloalkyl group and (B) a peptide component of a luminescent complex; (ii) a second fusion of (A) a second modified dehalogenase enzyme capable of covalently binding to a haloalkyl group and (B) a polypeptide component of a luminescent complex, and (iii) a substrate for the luminescent complex. Detection of luminescence indicates that the first modified dehalogenase enzyme binds to the haloalkyl groups on the DNA at a density sufficient to form a bioluminescent complex. The amount of luminescence is thus proportional to the amount of DNA synthesized in the presence of the haloalkyl-modified deoxynucleoside.

[0108] In some embodiments, the amount of synthesized DNA is a readout for the amount of cell proliferation. Thus, in some embodiments, methods are provided for detecting / monitoring the amount of cell proliferation using the systems and methods described herein.

[0109] In some embodiments, provided herein are methods of detecting a nucleic acid in a cell, comprising: (a) expressing in the cell: (i) a first fusion of (A) a first modified dehalogenase enzyme capable of covalently binding to a haloalkyl group and (B) a peptide component of a luminescent complex; (ii) a second fusion of (A) a second modified dehalogenase enzyme capable of covalently binding to a haloalkyl group and (B) a polypeptide component of a luminescent complex; (b) modifying the nucleic acid with a haloalkyl group by a method herein; (c) contacting the cell with a substrate for the luminescent complex; and (d) detecting luminescence from the luminescent complex, wherein the luminescence indicates that the density of haloalkyl labels on the nucleic acid is sufficient to allow binding of the first fusion and the second fusion at a location along the nucleic acid that promotes formation of a luminescent complex.

[0110] In some embodiments, provided herein is a method for detecting nucleic acid in a cell, comprising: (a) modifying a nucleic acid with a haloalkyl group by the method herein; (b) lysing the cell to produce a cell lysate containing a haloalkyl-modified nucleic acid; (c) contacting the cell lysate with (i) (A) a fusion of a modified dehalogenase enzyme capable of covalently binding to a haloalkyl group and (B) a luminescent protein; and (iii) a substrate for the luminescent complex; (d) detecting luminescence from the luminescent protein, the luminescence being proportional to the amount of haloalkyl-modified nucleic acid. In some embodiments, when a luminescent protein (e.g., luciferase (e.g., NANOLUC)) is used as the detectable part of the fusion, a washing step is required before detecting luminescence to ensure that the luminescence detected is that of the DNA-bound luminescent protein. Suitable methods for washing free reagents from DNA are understood in the art.

[0111] In some embodiments, provided herein are methods of using a three-part complementation system for detecting a nucleic acid in a cell, the method comprising: (a) modifying a nucleic acid with a haloalkyl group by the methods herein; (b) lysing the cell to produce a cell lysate comprising the haloalkyl-modified nucleic acid; (c) contacting the cell lysate with (i) a first fusion of (A) a first modified dehalogenase enzyme capable of covalently binding to a haloalkyl group and (B) a first peptide component of a luminescent complex; (ii) a second fusion of (A) a second modified dehalogenase enzyme capable of covalently binding to a haloalkyl group and (B) a second peptide component of a luminescent complex, (iii) a polypeptide component of a luminescent complex; and (iv) a substrate for the luminescent complex; and (d) detecting luminescence from the luminescent complex, wherein the luminescence indicates a sufficient density of haloalkyl incorporation into the nucleic acid to allow for binding of the first fusion and the second fusion at a position along the nucleic acid that promotes formation of a luminescent complex.

[0112] In some embodiments, assays are performed to monitor the rate of cell proliferation and / or DNA synthesis in a cell(s) in response to a selected environmental condition or stimulus. For example, the systems and methods herein are used to monitor the rate of DNA synthesis and / or cell proliferation in response to a drug, compound, external stimulus, etc. In some embodiments, the methods herein include exposing the cells to the stimulus or condition. In some embodiments, the stimulus or condition is applied before, after, or simultaneously with the addition of a haloalkyl modified deoxynucleoside to the cells (or cell culture medium). In some embodiments, the panel of cells is exposed to the stimulus for a variable amount of time prior to cell lysis, thereby allowing the effect of the stimulus to be observed over time. In some embodiments, the stimulus or condition may be applied to the cells at any step in the methods described herein, e.g., prior to the addition of the haloalkyl modified deoxynucleoside; after the addition of the haloalkyl modified deoxynucleoside but prior to cell lysis, etc. In some embodiments, the stimulus results in a change in the rate of cell proliferation / DNA synthesis. In some embodiments, the stimulus results in cell death. In some embodiments, the stimulus results in enhanced cell proliferation.

[0113] The present invention relates to the incorporation of novel modified nucleosides together with bioluminescence detection, thus enabling a more user-friendly assay by utilizing the sensitivity offered by bioluminescence-based detection in a plate-based assay and minimizing sample preparation steps using the NANOBiT "no wash" detection approach.

[0114] Without limitation, target cells whose replication and / or DNA synthesis are measurable by embodiments herein may include any cell from any source that can be labeled using the materials and methods provided herein. In some embodiments, the target cell is derived from a patient. In some embodiments, the target cell is of a cell type commonly used in cell culture experiments and / or clinical settings. In some embodiments, the target cell is derived from a carcinoma, sarcoma, leukemia, lymphoma, multiple myeloma, melanoma, brain or spinal tumor, germ cell tumor, neuroendocrine tumor, or carcinoid tumor. In some embodiments, the target cell is any cancerous or non-cancerous primary cell. In some embodiments, the target cell is a stem cell or stem cell-derived cell derived from a variety of different sources, including, but not limited to, bone marrow, embryonic germ cells or blood, including yolk sac, spleen, peripheral blood and umbilical cord blood, adipose tissue, and other tissues and organs. In some embodiments, the target cell is a hematopoietic stem cell, an endothelial progenitor cell, an embryonic stem cell, or a mesenchymal stem cell.

[0115] The cell-permeable haloalkyl-modified nucleosides (e.g., haloalkyl-modified deoxyuridines) herein provide the ability to modify newly synthesized DNA in specific cell types of interest, including but not limited to primary cells or cells isolated from patient samples, without the need to genetically engineer the cells. This type of DNA modification allows the rate of DNA synthesis in a population of cells to be tracked using a sensitive and quantitative bioluminescent approach. Modifications can be measured as an endpoint or in real time using a convenient "add-and-read" format that is high-throughput and applicable to many different assay platforms.

[0116] The embodiments herein are not limited to the components described herein, such as HALOTAG, NANOLUC, NANOBiT, NanoTriP, etc. Rather, other modified dehalogenases (e.g., U.S. Pat. No. 7,238,842; U.S. Pat. No. 7,425,436; U.S. Pat. No. 7,429,472; U.S. Pat. No. 7,867,726, each of which is incorporated herein by reference in its entirety) and complementary detection systems (e.g., other bipartite, tripartite, and multipartite bioluminescent complex systems (e.g., U.S. Provisional Patent Application No. 62 / 684,014; International Application No. PCT / US19 / 36844; PCT Application No. PCT / US14 / 26354; and / or U.S. Pat. No. 9,797,889, each of which is incorporated herein by reference in its entirety) also find use in embodiments herein. The reagents also include fluorescent proteins or fragments or non-fluorescent subunits of fluorescent proteins that form fluorescent sites upon complementation. For example, fluorescent proteins or fragments or non-fluorescent subunits of fluorescent proteins include those described by Feng et al., (Nature Communications, vol. 8, "Improved split fluorescent proteins for endogenous protein labeling” (2017)), Foglieni et al., (Scientific Reports, vol. 7, “Split GFP technologies to structurally characterize and quantify functional biomolecular interactions of FTD-related proteins” (2017)), and Koraichi et al., (Journal of Cell Science, vol. 131, “High-content tripartite split-GFP cell-based assays to screen for modulators of small GTPase activation” (2018)).For example, in some embodiments, the detection agent comprises a HALOTAG fusion component of a split fluorescent protein that is assembled and detected upon attachment of the HALOTAG moiety to a haloalkyl-modified nucleic acid according to the methods described herein.

[0117] As will be appreciated by those skilled in the art based on the present disclosure, the methods and assays herein can detect any cellular response that directly or indirectly leads to a change in the rate of cellular DNA synthesis. In some embodiments, the cellular response occurs as a result of the cell itself responding to a physiological stimulus. In other embodiments, the cellular response occurs as a result of an experimental manipulation (e.g., exposing the cell to a drug or toxin).

[0118] In some embodiments, the methods, assays, materials, and reagents herein find use in assays to determine the effectiveness of a particular treatment or therapy for killing diseased cells (e.g., cancer cells, tumor cells, etc.). For example, methods are provided herein for assaying the sensitivity of biopsied tumor cells to chemotherapy by monitoring the rate of DNA synthesis of the cells after treatment. Methods are also provided for determining in vitro drug sensitivity and / or chemosensitivity of target cell types. In some embodiments, the methods, assays, materials, and reagents herein find use in assays to determine the effect of a particular drug or condition on the rate of DNA synthesis in a cell population.

[0119] In some embodiments, the target cells may be of any suitable type for which a researcher, clinician, or other user wishes to monitor cell death. The cells may be solid tumor cells (e.g., from cell culture, biopsied from a subject, etc.), non-solid cancer cells, non-cancer cells, healthy human cells, cells obtained from model animals, cell lines, etc.

[0120] Embodiments of the present disclosure also include kits that include the various components described herein. Embodiments of the present disclosure may include kits that include a haloalkyl modified nucleoside (e.g., deoxyuridine) and one or more components of a bioluminescent complex (e.g., each component is fused or attached to a modified dehalogenase (e.g., HALOTAG)). In some embodiments, the kit may also include a luminogenic substrate. The kit may include a container and / or instructions. In some embodiments, the kit includes a donor DNA template that includes a sequence encoding a peptide or polypeptide (e.g., HiBiT, LgBiT) or a modified dehalogenase protein (e.g., HALOTAG).

[0121] In some embodiments, the kit may include various detection reagents, including, but not limited to, a container containing a haloalkyl modified nucleoside (e.g., deoxyuridine), a container containing a first component of a bioluminescent complex (e.g., fused to HALOTAG), a container containing a second component of a bioluminescent complex (e.g., fused to HALOTAG), and optionally a container containing a third component of a bioluminescent complex. In some embodiments, the components of the bioluminescent complex are provided in a single container or separate containers. The kit may also include a luminogenic substrate (e.g., a NANO-GLO luciferase assay substrate). The kit may also include various buffers and other reagents required to perform a bioluminescent bioassay.

[0122] Experiments performed during the development of embodiments herein, as well as previous work on some components of the assays, kits, etc. herein, demonstrate the modularity of the various components. For example, a nucleoside (e.g., deoxyuridine) may be attached directly or by a variety of different linkers to a variety of haloalkyl groups that are suitable substrates for the modified dehalogenase. Similarly, a modified dehalogenase (e.g., HALOTAG or a structurally or functionally related dehalogenase) may be fused or linked to any suitable detection reagent (e.g., a multipart complementation system (e.g., bipartite (e.g., NANOBiT), tripartite (e.g., NanoTrip), etc.), a bioluminescent polypeptide, peptide or polypeptide component such as a fluorophore) without altering the function of the modified dehalogenase. The peptide or polypeptide components of the multipartite complementation system (e.g., bipartite (e.g., NANOBiT), tripartite (e.g., NanoTrip), etc.) may be fused or linked to a variety of other components, such as fluorophores, modified dehalogenases (e.g., HALOTAG or structurally or functionally related dehalogenases), while retaining the ability to form an active bioluminescent complex. In light of the modularity of the components described herein, any combination of such components (e.g., as fusions, linked pairs, together in a kit or assay, etc.) is contemplated and within the scope of the present invention.

[0123] In some embodiments, the kit comprises a haloalkyl modified nucleoside (e.g., deoxyuridine); a modified dehalogenase capable of forming a covalent bond with its substrate (e.g., HALOTAG or a structurally or functionally related dehalogenase) fused to a polypeptide component of a bioluminescent complex; and a modified dehalogenase capable of forming a covalent bond with its substrate (e.g., HALOTAG or a structurally or functionally related dehalogenase) fused to a peptide component of a bioluminescent complex (e.g., a peptide that exhibits low affinity for the polypeptide component (e.g., requiring enhanced complex formation); where the peptide and polypeptide components form a bioluminescent complex when brought into appropriate proximity / orientation with one another. In some embodiments, the kit further comprises a substrate for the bioluminescent complex. In some embodiments, assays utilizing the aforementioned components are provided.

[0124] In some embodiments, the kit comprises a haloalkyl modified nucleoside (e.g., deoxyuridine); a modified dehalogenase (e.g., HALOTAG or a structurally or functionally related dehalogenase) fused to a polypeptide component of a bioluminescent complex that can form a covalent bond with its substrate; and a fluorophore linked to a peptide component of the bioluminescent complex (e.g., a peptide that exhibits high affinity for the polypeptide component); where the peptide and polypeptide components form a bioluminescent complex upon colocalization. In some embodiments, the kit further comprises a substrate for the bioluminescent complex. In some embodiments, assays utilizing the aforementioned components are provided.

[0125] In some embodiments, the kit comprises a haloalkyl modified nucleoside (e.g., deoxyuridine); a modified dehalogenase (e.g., HALOTAG or a structurally or functionally related dehalogenase) fused to a first peptide component of a bioluminescent complex capable of forming a covalent bond with its substrate; a modified dehalogenase (e.g., HALOTAG or a structurally or functionally related dehalogenase) fused to a second peptide component of the bioluminescent complex capable of forming a covalent bond with its substrate; and a peptide component of a bioluminescent complex; wherein the first peptide, second peptide and polypeptide components form a bioluminescent complex when a capture agent binds to the capture element resulting in the peptide components being brought into proper proximity / orientation with respect to one another. In some embodiments, the kit further comprises a substrate for the bioluminescent complex. In some embodiments, assays utilizing the aforementioned components are provided.

[0126] Other suitable combinations of assay / kit components will be apparent to those of skill in the art based on the disclosure herein. EXAMPLES

[0127] experiment Example 1 Experiments were performed during the development of embodiments herein to demonstrate the incorporation of modified nucleosides (PBI-7931 and PBI-7960) into newly synthesized DNA and detection using NANOBiT technology. A549 cells plated at 500 cells / well were cultured for 4 hours in medium containing PBI-7931 (Figure 2A, top) or PBI-7960 (Figure 2A, bottom) at a final concentration of 10 uM. Cells without modified nucleosides were used as controls. After incubation, the medium was removed, cells were fixed, permeabilized, and DNA was denatured using acid treatment. To measure the number of modified nucleosides incorporated into newly synthesized DNA, HT-LgBiT and HT-SmBiT were added to the cells at a final concentration of 50 nM. After 1 hour of incubation, NANOLUC substrate was added and luminescence was measured (Figure 2B).

[0128] Example 2 Experiments were performed during the development of embodiments herein to demonstrate that inhibition of DNA replication can be measured using the methods described herein. A549 cells plated at 2,000 cells / well were treated with increasing concentrations of the DNA replication inhibitor doxorubicin for 2 hours in a tissue culture incubator. After 2 hours of treatment, compounds PBI-7931 or -7960 were added to the medium at a final concentration of 10 uM and the cells were returned to the tissue culture incubator for an additional 4 hours. No compound was added to control cells. To measure the amount of newly synthesized DNA, HT-LgBiT and HT-SmBiT were added to the cells at a final concentration of 50 nM. After 1 hour of incubation, NANOLUC substrate was added and luminescence was measured (Figure 3).

[0129] Example 3 Synthesis of compound PBI 7931 Synthesis of propargyl p-nitrophenyl carbonate (mz-1073) [ka] Propargyl alcohol (1 g, 17.8 mmol) and p-nitrophenyl chloromethane (5.39 g, 26.7 mmol) were mixed in 20 mL of dry THF. The mixture was stirred in an ice-water bath and pyridine (4.3 mL, 53.5 mmol) was slowly added to the reaction mixture. A white precipitate formed immediately. After the addition, the reaction mixture was kept stirring in an ice-water bath for an additional hour. The precipitate was removed by centrifugation. The solid was rinsed with 20 mL of acetonitrile and centrifuged again. The liquid portions were combined, concentrated, and purified by flash chromatography (heptane-ethyl acetate, 10-50%). Approximately 1.39 g of a white solid was obtained (35% yield).

[0130] Synthesis of Propargyl Chloro-PEG2 Carbamate (MZ-1074) [ka] Propargyl p-nitrophenyl carbonate (111 mg, 0.50 mmol) and chlorohexyl-PEG2-amine (102 mg, 0.46 mmol) were mixed in 2 mL of THF, followed by the addition of triethylamine (125 μL, 0.91 mmol). The mixture was stirred at room temperature. After 30 min, LC-MS showed + It showed product peaks at 306 and 308 (chloro isotopes) (no LC peak). Also unreacted carbonate was detected. An additional 100 mg of cyclohexyl-PEG2-amine was added. After an additional hour, no starting material (carbonate) was detected by LC-MS. The mixture was purified by flash chromatography (EtOAc-heptane, 0-20% in 15 min, 20-50% in 1 min) and the product was eluted with 50% EtOAc. (Due to the absence of a chromophore in the target molecule, elution fractions were detected by UV-Vis for by-products and by light scattering detector for the target molecule). Approximately 110 mg of the target molecule (colorless oil, 79% yield) was obtained.

[0131] Synthesis of PBI 7931 (mz-1075) [ka] 5-Iodo-dU (85 mg, 0.24 mmol, Chem-impex), tetrakis (24 mg, 0.024 mmol) and copper(I) iodide (9.14 mg, 0.048 mmol) were mixed together in 2.5 mL of DMF in a 100 mL round bottom flask. The system was evacuated and backfilled with nitrogen twice. A solution of propargyl chlorohexyl-PEG2 carbamate (110 mg, 0.36 mmol) in 2.5 mL of DMF was mixed with 65.6 μL of triethylamine (0.48 mmol) and the mixture was injected into the reaction flask. The entire clear solution was stirred at 25° C. overnight. LC-MS: MS at 290 nm + It showed major peaks at 532,534 (chloro isotopes). The mixture was purified by preparative HPLC to give about 30 mg of a white solid (23% yield).

[0132] Example 4 Synthesis of compound PBI 7960 4-((2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)carbamoyl)benzoic acid [ka] To a solution of terephthalic acid (2.97 g, 17.9 mmol) in anhydrous DMF (40 ml) was added diisopropylethylamine (12.5 ml, 71.5 mmol) followed by HATU (hexafluorophosphate azabenzotriazole tetramethyluronium, 3.40 g, 8.94 mmol). The solution was stirred for 10 min and 2-(2-((6-chlorohexyl)oxy)ethoxy)ethan-1-amine (2.0 g, 8.94 mmol) was added slowly. The resulting reaction mixture was then stirred overnight. The solution was extracted with ethyl acetate and acetic acid solution (2 M) and washed with brine. After drying over sodium sulfate, the organic solvent was evaporated and the residue was purified by flash chromatography. 1 H NMR(400MHz,CDCl3)δ8.11(m,2H),7.85(m,2H),6.83(s,1H),3.70-3.59(m,8H) ,3.52-3.45(m,4H),1.75-1.69(m,2H),1.58-1.54(m,2H),1.43-1.33(m,4H);MS m / z 371[M+H].

[0133] 2,5-Dioxopyrrolidin-1-yl 4-((2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)carbamoyl)benzoate [ka] To a solution of 4-((2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)carbamoyl)benzoic acid (1.02 g, 2.76 mmol) in dichloromethane was added diisopropylethylamine (0.96 ml, 5.51 mmol). TSTU (N,N,N',N'-tetramethyl-O-(N-succinimidyl)uronium tetrafluoroborate, 0.91 g, 3.03 mmol) was added subsequently and the reaction mixture was stirred for 20 min. The solvent was evaporated and the residue was purified by flash chromatography. 1 H NMR(400MHz,DMSO)δ8.84(t,J=8.0Hz,1H),8.20(m,2H),8.08(m,2H),3.62-3.54(m,6H),3.50-3.43 (m,4H),3.38-3.30(m,2H),2.91(s,4H),1.71-1.64(m,2H),1.49-1.42(m,2H),1.39-1.22(m,4H);MS m / z 468[M+H].

[0134] N1-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)-N4-(prop-2-yn-1-yl)terephthalamide (HW-0820) [ka] To a solution of 2,5-dioxopyrrolidin-1-yl 4-((2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)carbamoyl)benzoate (34 mg, 0.073 mmol) in DMF was added propargylamine (12 mg, 0.22 mmol). The reaction was stirred for 2 h and the solvent was evaporated to dryness. The residue was purified by flash chromatography. MS m / z 409 [M+H].

[0135] N1-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)-N4-(3-(1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)prop-2-yn-1-yl)terephthalamide (PBI 7960) [ka] Tetrakis(triphenylphosphine)palladium(0) (6.78 mg, 0.006 mmol), copper(I) iodide (2.24 mg, 0.012 mmol), triethylamine (12 mg, 0.117 mmol), and N1-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)-N4-(prop-2-yn-1-yl)terephthalamide (24 mg, 0.059 mmol) were added to a solution of 5-iodo-2'-deoxycytidine (21 mg, 0.059 mmol) in anhydrous dimethylformamide (5 mL). The orange reaction mixture was stirred at room temperature for 4 h under a nitrogen atmosphere. A few drops of 5% disodium salt of EDTA / H2O were then added to the reaction mixture and the contents were concentrated in vacuo. The resulting residue was purified on a silica gel column. MS m / z 635 [M+H].

[0136] Example 5 Benzamide linker synthesis Compound 1: 4-((2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)carbamoyl)benzoic acid [ka] Terephthalic acid (3.00 g, 18.06 mmol) and 20 ml of anhydrous DMF were added to a 250 ml round bottom flask, followed by diisopropylethylamine (12.58 ml, 72.23 mmol) and HATU (azabenzotriazole tetramethyluronium hexafluorophosphate, 3.43 g, 9.03 mmol). The solution was stirred for 10 minutes, after which 2-(2-((6-chlorohexyl)oxy)ethoxy)ethan-1-amine (2.02 g, 9.03 mmol) was added slowly. The resulting reaction mixture was sealed with a nitrogen balloon and stirred overnight at room temperature. The solution was extracted with ethyl acetate and acetic acid solution (2M) and washed with brine. After drying over sodium sulfate, the organic solvent was concentrated and the residue was purified by flash chromatography (10% grade methanol:DCM).1 H NMR (400MHz, chloroform-d) δ8.14-8.03(m,2H),7.88-7.82(m,2H),6.94(t,J=4.8Hz,1H),3.76-3.68(m,5H),3.62(dd,J=5.8,3.0H MS + 372,374

[0137] Compound 2: 2,5-Dioxopyrrolidin-1-yl 4-((2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)carbamoyl)benzoate [ka] Compound 1 (410 mg, 1.10 mmol) and 5 ml of dichloromethane were added to a 250 ml round bottom flask, followed by diisopropylethylamine (0.384 mL, 2.21 mmol) and TSTU (N,N,N',N'-tetramethyl-O-(N-succinimidyl)uronium tetrafluoroborate, 0.365 g, 1.21 mmol). The reaction mixture was sealed with a nitrogen balloon and stirred at room temperature for 20 min. The solvent was concentrated and the residue was purified by flash chromatography (20% grade acetone:DCM). 1 H NMR(400MHz,chloroform-d)δ8.20(d,J=8.2Hz,2H),7.92(d,J=8.2Hz,2H),6.86(d,J=5.6Hz,1H),3.72-3.63(m,6H),3.60(dd,J=5.9, 3.1Hz,2H), 3.49(dt,J=22.1,6.7Hz,4H),2.92(s,3H),2.17(s,1H),1.74(p,J=6.8Hz,2H),1.61-1.53(m,2H),1.48-1.27(m,4H). M.S. + 469,471.

[0138] Compound 3: N1-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)-N4-(prop-2-yn-1-yl)terephthalamide [ka] Compound 2 (110 mg, 0.235 mmol) and 4 ml of DMF were added to a 250 ml round bottom flask, followed by propargylamine (38.76 mg, 0.704 mmol). The reaction was sealed with a nitrogen balloon and stirred at room temperature for 20 minutes. The solution was concentrated and purified by flash chromatography (10% grade methanol:DCM). 1 H NMR (400MHz, chloroform-d) δ7.90-7.80(m,4H),6.87(d,J=5.7Hz,1H),6.36(d,J=5.4Hz,1H),4.27(dd ,J=5.2,2.6Hz,2H),3.73-3.64(m,6H),3.60(dd,J=5.7,3.0Hz,2H),3.51(t,J=6.7Hz,2H),3.46(t, J=6.7Hz,2H),2.73(s,3H),2.31(t,J=2.6Hz,1H),1.73(p,J=6.8Hz,4H),1.56(p,J=6.9Hz,4H),1.4 7-1.39(m,3H),1.39-1.35(m,2H),1.35-1.28(m,4H),1.25(s,3H),0.92-0.84(m,4H),0.83(s,1H). M.S. + 409,411

[0139] Compound 4a (PBI-9425): N1-(3-(4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2,5,6-tetrahydropyrimidin-5-yl)prop-2-yn-1-yl)-N4-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)terephthalamide [ka] 5-Iodo-dC (43.77 mg, 0.123 mmol, Chem-impx), tetrakis (7.63 mg, 0.007 mmol), and copper(I) iodide (3.37 mg, 0.02 mmol) were mixed in 2.5 mL of DMF in a 100 mL round bottom flask. The system was evacuated and backfilled with nitrogen twice. In a separate 20 mL vial, compound 3 (45 mg, 0.11 mmol) in 1.5 mL of DMF was mixed with 24 μL of triethylamine (0.173 mmol) and the mixture was injected into the reaction flask. The clear solution was stirred at room temperature for 2 h. The mixture was purified by preparative HPLC and concentrated to give approximately 15 mg of a white solid (21.43% yield, 93.33% purity). 1 H NMR (400MHz, methylene chloride-d2&3 drops of CD3OD) δ8.47(s,1H),7.89(d,J=8.0Hz,2H),7.82(d,J=7.9Hz,2H),6.07(d,J=6.1Hz, 1H),5.32(s,9H),4.41(d,J=5.4Hz,1H),4.27(s,2H),3.97(s,1H),3.86(d,J=12.2Hz,1H),3.76(d,J=12.2Hz,1H) ,3.68-3.58(m,7H),3.58-3.54(m,3H),3.47(dtd,J=28.9,6.7,2.2Hz,5H),3.35(s,1H),2.45-2.37(m,1H),2.19( MS + 634,636

[0140] Compound 4b (PBI-9429): N1-(3-(2-amino-7-((2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)prop-2-yn-1-yl)-N4-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)terephthalamide [ka] 5-Iodo-dG (42.96 mg, 0.110 mmol, Chem-impex), tetrakis (6.78 mg, 0.006 mmol), and copper(I) iodide (3.35 mg, 0.018 mmol) were mixed in 2.5 mL of DMF in a 100 mL round bottom flask. The system was evacuated and backfilled with nitrogen twice. In a separate 20 ml vial, compound 3 (40 mg, 0.098 mmol) in 1.5 mL of DMF was mixed with 30 μL of triethylamine (0.215 mmol) and the mixture was injected into the reaction flask. The clear solution was stirred overnight at room temperature. The mixture was purified by preparative HPLC and concentrated to give approximately 24 mg of a white solid (36.45% yield, 97.45% purity). 1 H NMR (400MHz, methanol-d4) δ8.00-7.89(m,4H),7.22(s,1H),6.37(t,J=7.2Hz,1H),4.46(dd,J=6.1,3. 1Hz,1H),4.41(s,2H),3.93(t,J=3.5Hz,1H),3.79-3.72(m,1H),3.67(td,J=10.5,8.8,4.8Hz,5H),3 .60(d,J=5.5Hz,4H),3.50(dt,J=20.2,6.9Hz,4H),2.49(dt,J=14.0,7.0Hz,1H),2.30-2.21(m,1H), 1.72(p,J=7.0Hz,2H),1.56(p,J=7.1Hz,2H),1.42(t,J=7.8Hz,2H),1.34(dt,J=16.7,8.8Hz,3H);MS + 634,636

[0141] Compound 4c (PBI-9428): N1-(3-(4-amino-7-((2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)prop-2-yn-1-yl)-N4-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)terephthalamide [ka] 5-Iodo-dA (41.21 mg, 0.110 mmol, Chem-impex), tetrakis (6.78 mg, 0.006 mmol), and copper(I) iodide (3.35 mg, 0.018 mmol) were mixed in 2.5 mL of DMF in a 100 mL round bottom flask. The system was evacuated and backfilled with nitrogen twice. In a separate 20 ml vial, compound 3 (40 mg, 0.098 mmol) in 1.5 mL of DMF was mixed with 30 μL of triethylamine (0.215 mmol) and the mixture was injected into the reaction flask. The clear solution was stirred overnight at room temperature. The mixture was purified by preparative HPLC and concentrated to give approximately 10 mg of a white solid (15.56% yield, 99.68% purity). 1 H NMR (400MHz, methanol-d4) δ8.27(s,1H),8.00-7.88(m,5H),6.62(t,J=6.5Hz,1H),4.51(h,J=2 .9Hz,1H),4.36(d,J=2.4Hz,2H),4.01(p,J=3.3Hz,1H),3.83-3.75(m,1H),3.75-3.67(m,2H) ),3.67-3.56(m,7H),3.55-3.43(m,4H),2.54(dt,J=13.9,6.7Hz,1H),2.40(ddt,J=13.3,6. MS + 657,659

[0142] Example 6 Carbamate Linker Synthesis Compound 1: 4-Nitrophenylprop-2-yn-1-yl carbonate [ka] Propargyl alcohol (1 g, 17.8 mmol), p-nitrophenyl chloroformate (5.39 g, 26.8 mmol) and 20 mL of dry THF were added to a 250 mL round bottom flask and sealed with a nitrogen balloon. The mixture was stirred in an ice-water bath and pyridine (4.3 mL, 53.5 mmol) was slowly injected into the flask. A white precipitate formed immediately. After pyridine addition, the mixture was continued to stir in the ice-water bath for an additional hour. The precipitate was removed by centrifugation and the resulting solid was rinsed with 20 mL of THF and centrifuged again. The supernatant portions were combined, concentrated and purified by flash chromatography (50% grade EtOAc:heptane). 1 H NMR (400 MHz, chloroform-d) δ 8.39-8.32 (m, 2H), 8.32-8.25 (m, 10H), 7.54-7.46 (m, 2H), 7.45-7.37 (m, 10H), 4.88 (d, J = 2.5 Hz, 10H), 2.62 (t, J = 2.5 Hz, 5H), 1.32-1.22 (m, 1H). MS of the phenoxide by-product was not stable in the acidic conditions. + Only 138 were admitted.

[0143] Compound 2: Prop-2-yn-1-yl (2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)carbamate [ka] Compound 1 (300 mg, 1.36 mmol), chlorohexyl-PEG2-amine (324.71 mg, 1.25 mmol) and 6 mL of THF were added to a 250 ml round bottom flask, followed by triethylamine (344.1 μL, 2.47 mmol). The mixture was stirred at room temperature for 30 minutes. LC-MS showed that the MS +It showed product peaks with 306 and 308 (no LC peaks) and unreacted carbonate. An additional 300 mg of chlorohexyl-PEG2-amine was added and stirring was continued overnight. The resulting LCMS showed no starting material (carbonate). The mixture was purified by flash chromatography (40% grade EtOAc:heptane). As no chromophore was present in the target molecule, the product was detected by UV-Vis and light scattering detectors. 1 H NMR(400MHz,chloroform-d)δ5.36(s,1H),4.68(d,J=2.4Hz,3H),3.65-3.35(m,20H),2 .54-2.43(m,2H),1.78(p,J=6.9Hz,3H),1.62(d,J=7.2Hz,5H),1.52-1.31(m,7H).

[0144] Compound 3a (PBI-9391): 3-(4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-5-yl)prop-2-yn-1-yl(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)carbamate [ka] 5-Iodo-dC (91.54 mg, 0.403 mmol, Chem-impx), tetrakis (24.11 mg, 0.021 mmol), and copper(I) iodide (9.18 mg, 0.048 mmol) were mixed in 2.5 mL of DMF in a 100 mL round bottom flask. The system was evacuated and backfilled with nitrogen twice. In a separate 20 mL vial, compound 3 (110 mg, 0.36 mmol), 1.5 mL of DMF, and 24 μL of triethylamine (0.173 mmol) were mixed and injected into the reaction flask. The clear solution was stirred overnight at room temperature. The mixture was purified by preparative HPLC and concentrated to give approximately 44 mg of a white solid (yield 23.04%, purity 85.58%). 1H NMR (400 MHz, chloroform-d) δ 8.56 (s, 1H), 6.07 (s, 1H), 6.02-5.97 (m, 1H), 4.81 (s, 2H), 4.49 (s, 1H), 4.00 (dd, J = 15.4, 6.1 Hz, 3H), 3.88 (s, 2H), 3.70-3.58 (m, 10H), 3.57 (d, J = 5.2 Hz, 10H ),3.49(dt,J=27.9,6.7Hz,22H),3.40-3.31(m,8H),3.22(s,2H),3.06(s,1H),2.49(s,1H) ,2.27(s,1H),1.76(p,J=6.9Hz,8H),1.59(t,J=7.3Hz,7H),1.39(dp,J=28.7,7.8Hz,16H). M.S. + 531,533.

[0145] Compound 3b (PBI-9392): 3-(2-amino-7-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)prop-2-yn-1-yl(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)carbamate [ka] 5-Iodo-dA (94.04 mg, 0.240 mmol, Chem-impx), tetrakis (27.71 mg, 0.024 mmol), and copper(I) iodide (9.13 mg, 0.048 mmol) were mixed in 2.5 mL of DMF in a 100 mL round bottom flask. The system was evacuated and backfilled with nitrogen twice. In a separate 20 mL vial, compound 3 (110 mg, 0.36 mmol), 1.5 mL of DMF, and 67 μL of triethylamine (0.48 mmol) were mixed and injected into the reaction flask. The clear solution was stirred overnight at room temperature. The mixture was purified by preparative HPLC and concentrated to give approximately 39 mg of a white solid (28.53% yield, 91.73% purity). 1H NMR (400MHz, methylene chloride-d2) δ10.90(s,2H),7.57(s,1H),6.94(s,2H),5.98(d,J=8.2Hz,2H),5.32(s,16H),5.03(d,J=1 6.0Hz,2H),4.90(d,J=16.0Hz,2H),4.77(d,J=5.2Hz,2H),4.10(s,2H),3.91(d,J=12.1Hz,2H),3.81(d,J=12.2Hz,2 H),3.54(dq,J=15.6,8.8,6.3Hz,20H),3.42(t,J=6.9Hz,7H),3.37(s,3H),2.96(s,1H),2.21(d,J=11.1Hz,2H),1.7 5(p,J=6.9Hz,6H),1.56(s,4H),1.43(p,J=7.4Hz,6H),1.34(q,J=7.8Hz,6H),1.26(s,2H),0.87(d,J=11.1Hz,1H);MS + 570,572.

[0146] Compound 3c (PBI-9393): 3-(4-amino-7-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)prop-2-yn-1-yl(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)carbamate [ka] 5-Iodo-dG (94.31 mg, 0.240 mmol, Chem-impx), tetrakis (28.97 mg, 0.025 mmol), and copper(I) iodide (9.55 mg, 0.05 mmol) were mixed in 2.5 mL of DMF in a 100 mL round bottom flask. The system was evacuated and backfilled with nitrogen twice. In a separate 20 mL vial, compound 3 (110 mg, 0.36 mmol), 1.5 mL of DMF, and 70 μL of triethylamine (0.5 mmol) were mixed and injected into the reaction flask. The clear solution was stirred overnight at room temperature. The mixture was purified by preparative HPLC and concentrated to give approximately 113 mg of a white solid (81.35%, purity 98.23%). 1H NMR (400 MHz, chloroform-d) δ 7.83 (s, 1H), 6.99 (s, 1H), 6.20 (t, J = 6.9 Hz, 1H), 5.44 (t, J = 5.7 Hz, 1H), 4.53 (d, J = 2.2 Hz, 2H), 4.42 (dt, J = 5.6, 2.7 Hz, 1H), 3.88 (d, J = 3.0 Hz, 1H), 3.64 (s, 1H), 3.60 -3.52(m,1H),3.38-3.12(m,14H),2.39(td,J=12.0,10.5,5.2Hz,1H),2.16(ddd,J=13.6,6.0, MS + 554,556.

[0147] Example 7 Experiments were performed during development of embodiments herein to demonstrate incorporation of modified nucleosides (PBI-9391, PBI-9392, and PBI-9393) into newly synthesized DNA and detection using NANOBiT technology (Figure 4). A549 cells plated at 5000 cells / well were cultured for 4.5 hours in medium containing PBI-9391, PBI-9392, or PBI-9393 at a final concentration of 20 uM (light blue bars) or 50 uM (dark blue bars). Cells without modified nucleosides were used as controls (brown bars). Incorporation of modified nucleosides into DNA was determined by removing the medium, fixing and permeabilizing the cells, denaturing the DNA, and incubating with HaloTag-LgBiT (HT-LgBiT) and HaloTag-SmBiT (HT-SmBiT) diluted in PBS containing 0.01% BSA to a final concentration of 50 nM. After 2 h of incubation, the reagents were removed, samples were washed with PBS, NanoLuc substrate was added, and luminescence was measured (Figure 4).

[0148] Example 8 An experiment was conducted during development of an embodiment herein to demonstrate incorporation of modified nucleosides (PBI-9391, PBI-9392, PBI-9393 and PBI-7960) into newly synthesized DNA and detection by NanoBiT technology with all probes added together at final 5 or 12.5 uM, respectively (Figure 5). The experiment was performed with A549 cells plated at 5,000 and 1,000 cells per well, similar to that described in Example 7. Figure 5 shows the increase in light output in the presence of modified nucleosides added at 5 uM (light blue bars) or 12.5 uM (dark blue bars) compared to control cells (brown bars).

[0149] Example 9 An experiment was performed during the development of an embodiment herein to demonstrate that incorporation of modified chloroalkane nucleosides can be measured without DNA denaturation (Figure 6). A549 cells plated at 5000 cells / well were cultured in medium containing PBI-7960 at a final concentration of 10 uM for 0.5 h (light blue bars) or 4 h (dark blue bars). Cells without modified nucleosides were used as a control (brown bars). Incorporation of modified nucleosides into DNA was determined by removing the medium, fixing and permeabilizing the cells, and incubating with HT-LgBiT and HT-SmBiT diluted in PBS with 0.01% BSA at a final concentration of 25 nM. After 1 h of incubation, NanoLuc substrate was added and luminescence was measured.

[0150] Example 10 Experiments during development of embodiments herein were performed to demonstrate that incorporation of modified chloroalkane nucleosides into newly synthesized DNA can be measured directly in cell lysates (Figure 7). A549 cells plated at 5,000 cells / well were incubated in medium containing PBI-9191 at a final concentration of 20 uM for 2 hours at 37°C (dark blue bars), on ice (light blue bars), or probe was added and immediately removed (brown bars). Incorporation of modified nucleosides into DNA was determined by removing medium, washing cells with PBS, and dissolving in passive lysis buffer (Promega; Cat. No E1941) containing HT-LgBiT and HT-SmBiT at a final concentration of 3.2 nM. After 1 hour of incubation, NanoLuc substrate was added and luminescence was measured.

[0151] array WT OgLuc (SEQ ID NO: 1): MTLADF WT OgLuc Lg (SEQ ID NO: 2): MFTLADFVGDWQQTAGYNQDQVLEQGGLSSLFQALGVSVTPIQKVVLSGENGLKADIHVIIPYEGLSGFQMGLIEMIFKVVYPVDDHHFKIILHYGTLVIDGVTPNMIDYFGRPYPGIAVFDGKQITVTGTLWNGNKIYDERLINPD WT OgLuc β9 (SEQ ID NO: 3): GSLLFRVTIN WT OgLuc β10 (SEQ ID NO: 4): GVTGWRLCENILA NanoLuc (SEQ ID NO:5): MVFTLEDFVGDWRQTAGYNLDQVLEQGGVSSLFQNLGVSVTPIQRIVLSGENGLKIDIHVIIPYEGLSGDQMGQIEKIFKVVYPVDDHHFKVILHYGTLVIDGVTPNMIDYFGRPYEGIAVFDGKKITVTGTLWNGNKIIDERLINPDGSLFRVTINGVTGWRLCERILA NanoLuc Lg (SEQ ID NO: 6): MVFTLEDFVGDWRQTAGYNLDQVLEQGGVSSLFQNLGVSVTPIQRIVLSGENGLKIDIHVIIPYEGLSGDQMGQIEKIFKVVYPVDDHHFKVILHYGTLVIDGVTPNMIDYFGRPYEGIAVFDGKKITVTGTLWNGNKIIDERLINPD NanoLuc β9 (SEQ ID NO: 7): GSLLFRVTINV NanoLuc β10 (SEQ ID NO: 8): GVTGWRLCERILA LgBiT (SEQ ID NO: 9): MVFTLEDFVGDWRQTAGYNLDQVLEQGGVSSLFQNLGVSVTPIQRIVLSGENGLKIDIHVIIPYEGLSGDQMGQIEKIFKVVYPVDDHHFKVILHYGTLVIDGVTPNMIDYFGRPYEGIAVFDGKKITVTGTLWNGNKIIDERLINPDGSLLFRVTIN SmBiT (SEQ ID NO: 10): VTGYRLFEEIL HiBiT (SEQ ID NO: 11): VSGWRLFKKIS LgTrip(3546) (SEQ ID NO: 12): MKHHHHHHVFTLDDFVGDWEQTAAYNLDQVLEQGGVSSLLQNLAVSVTPIMRIVRSGENALKIDIHVIIPYEGLSADQMAQIEEVFKVVYPVDDHHFKVILPYGTLVIDGVTPNKLNYFGRPYEGIAVFDGKKITTTGTLWNGNKIIDERLITPD SmTrip9 (SEQ ID NO: 13): GSMLFRVTINS β9 / β10 dipeptide (SEQ ID NO: 14): GSMLFRVTINSVSGWRLFKKIS SmTrip10 (SEQ ID NO: 15): VSGWRLFKKIS HaloTag (SEQ ID NO: 16): MAEIGTGFPFDPHYVEVLGERMHYVDVGPRDGTPVLFLHGNPTSSYVWRNIIPHVAPTHRCIAPDLIGMGKSDKPDLGYFFDDHVRFMDAFIEALGLEEVVLVIHDWGSALGFHWAKRNPERVKGIAFMEFIRPIPTWDEWPEFARET FQAFRTTDVGRKLIIDQNVFIEGTLMGVVRPLTEEVEMDHYREPFLNPVDREPLWRFPNELPIAGEPANIVALVEEYMDWLHQSPVPKLLFWGTPGVLIPPAEAARLAKSLPNCKAVDIGPGLNLLQEDNPDLIGSEIARWLSTLEISG Assembled sequence of the bioluminescent complex (SEQ ID NO:17): MVFTLDDFVGDWEQTAAYNLDQVLEQGGVSSLLQNLAVSVTPIMRIVRSGENALKIDIHVIIPYEGLSADQMAQIEEVFKVVYPVDDHHFKVILPYGTLVIDGVTPNKLNYFGRPYEGIAVFDGKKITTTGTLWNGNKIIDERLITPDGSMLFRVTINSVTGYRLFEEIL WT strand 9-SmBiT (SEQ ID NO: 18): GSMLFRVTINSVTGYRLFEEIL LgTrip 3546(1-8) (SEQ ID NO: 19): MVFTLDDFVGDWEQTAAYNLDQVLEQGGVSSLLQNLAVSVTPIMRIVRSGENALKIDIHVIIPYEGLSADQMAQIEEVFKVVYPVDDHHFKVILPYGTLVIDGVTPNKLNYFGRPYEGIAVFDGKKITTTGTLWNGNKIIDERLITPD

Claims

1. Formula (I): 【Chemistry 1】 or a salt thereof, wherein B is a nucleobase; L is a linker; A compound or a salt thereof, wherein A is a haloalkyl group.

2. Formula (I) 【Chemistry 2】 2. The compound of claim 1, comprising:

3. 2. The compound according to claim 1, or a salt thereof, wherein L comprises one or more groups independently selected from alkyl, cyclic alkyl, alkylene, alkenylene, alkynylene, arylene, -O-, -NH-, and -C(O)-.

4. L is -(CH 2 ) m -, -CH=CH-, -C≡C-, -C(O)NH-, -OC(O)NH-, -CH 2 CH 2 O- and -CH 2 O-, The compound according to claim 1, or a salt thereof, wherein m is 1 to 6.

5. L 【Chemistry 3-1】 【Chemistry 3-2】 and p, q, r and s are each independently 1 to 6, or a salt thereof.

6. A is C 2 -C 12 The compound or salt thereof according to claim 1, which is a haloalkyl group.

7. A is of the formula: -(CH 2 ) n -X 2. The compound of claim 1, having the formula: wherein n is 4, 5, 6, 7, or 8, and X is halo, or a salt thereof.

8. 8. The compound of claim 7, wherein n is 6 and X is chloro.

9. The compound has the formula (II): 【Chemistry 4-1】 【Chemistry 4-2】 and p, q, r, and s are independently 1 to 6.

10. The compound has the formula (III): 【Chemistry 5-1】 【Chemistry 5-2】 and p, q, r, and s are independently 1 to 6.

11. The compound has the formula (IV): 【Chemistry 6-1】 【Chemistry 6-2】 and p, q, r, and s are independently 1 to 6.

12. The compound has the formula (V): 【Chemistry 7-1】 【Chemistry 7-2】 and p, q, r, and s are independently 1 to 6.

13. The compound is selected from the group consisting of: 【Chemistry 8-1】 【Chemistry 8-2】 【Chemistry 8-3】 【Chemistry 8-4】 【Chemistry 8-5】 【Chemistry 8-6】 【Chemistry 8-7】 【Chemistry 8-8】 【Chemistry 8-9】 【Chemistry 8-10】 2. The compound of claim 1 , selected from:

14. The compound is selected from the group consisting of: 【Chemistry 9】 14. The compound of claim 13, selected from:

15. A polynucleotide chain comprising one or more of deoxyadenosine, deoxythymidine, deoxycytidine, deoxyguanosine, and the compound according to any one of claims 1 to 14.

16. 15. A method of incorporating a haloalkyl group-modified nucleoside of any one of claims 1 to 14 into DNA replication in a cell, comprising the steps of contacting the cell with a compound of any one of claims 1 to 14, allowing the compound to enter the cell, converting the compound to a modified deoxynucleotide triphosphate by an enzyme in the cell, and incorporating the modified deoxynucleotide triphosphate into DNA replication during DNA synthesis.

17. The method of claim 16 , wherein the cells are cultured in a medium containing the compound.

18. 17. A nucleic acid produced by the method of claim 16.

19. 17. A cell comprising nucleic acid produced by the method of claim 16.

20. A method for detecting a haloalkyl-labeled nucleic acid in a cell, the nucleic acid being labeled with a compound according to any one of claims 1 to 14, comprising: (a) lysing the cells to produce a cell lysate comprising the haloalkyl-labeled nucleic acid; (b) contacting the cell lysate with (i) a modified dehalogenase capable of covalently binding to a haloalkyl group and (ii) a reporter capable of generating a detectable signal; (c) attaching the modified dehalogenase to a haloalkyl group on the nucleic acid; (d) detecting the detectable signal from the reporter; A method comprising:

21. 21. The method of claim 20, wherein the reporter is a luciferase, a fluorophore, a fluorescent protein, a reporter complex, or a detectable enzyme.

22. 21. The method of claim 20, further comprising between steps (c) and (d) a step of washing away any reporter linked to the modified dehalogenase that is not bound to the haloalkyl-labeled nucleic acid.

Images